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Abstract 
Natural killer (NK) cells recognize virally infected cells through a balance of 
activating and inhibitory signals received from target cells.  The NK cell recognition of 
human immunodeficiency virus type 1 (HIV-1) infected cells is inefficient due to 
multiple viral immune evasion strategies.  The HIV negative factor (Nef) selectively 
downmodulates MHC-I surface expression, where expression of the NK cell inhibitory 
allotypes HLA-C and -E is not affected.  Here I show NK cell recognition of HIV-
infected cells is also limited by insufficient NK cell activating ligand expression.  NK cell 
activating ligand expression is modulated by three HIV-1 accessory proteins: viral 
infectivity factor (Vif), viral protein R (Vpr) and Nef.  Vpr upregulates NK cell activating 
ligand expression.  However, the Vif and Nef accessory proteins limit these detrimental 
effects of Vpr expression. 
The cellular cytidine deaminase APOBEC3G is an intrinsic restriction factor that 
suppresses HIV infection.  It acts by causing G to A hypermutation and inhibiting viral 
genome synthesis.  HIV counteracts APOBEC3G through the activity of Vif, which 
promotes the degradation of APOBEC3G.  In other contexts, DNA damage like that 
caused by APOBEC3G is known to activate NK cell lysis by upregulating NK cell 
activating ligands.  However, a possible effect of APOBEC3G-induced DNA damage on 
the cellular immune response has not yet been examined.  This dissertation shows that 
APOBEC3G expression levels correlate with activation of DNA repair pathways and 
subsequent expression of NK cell activating ligands in primary T lymphocytes.  
Expression of Vif mitigates this effect and partially rescues infected cells from NK cell 
lysis.   A Vif mutant unable to bind APOBEC3G was less effective at counteracting the 
effects of APOBEC3G on the DNA damage response and NK cell activating ligand 
expression.  Interestingly, APOBEC3G and HIV infection activated an early stage in the 
DNA damage response; however downstream DNA repair signaling and upregulation of 
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NK cell activating ligands required HIV Vpr expression.  These results define a new role 
for APOBEC3G acting not just as an intrinsic antiviral factor but also as an activator of 
the innate cellular immune response. 
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Chapter 1  
Introduction 
In recent years human immunodeficiency virus type 1 (HIV-1) has spread to an 
estimated 33.4 million people worldwide, a 20% increase since the year 20001.  These 
staggering numbers indicate that a greater understanding of HIV biology is needed to 
eradicate this growing epidemic.  This dissertation addresses HIV’s ability to evade 
recognition by the immune system, with the goal of revealing new ways to target HIV 
infected cells.  
HIV-1 replication 
HIV-1 is a member of the Retroviridae family of viruses that has a single stranded 
RNA (ssRNA) genome consisting of gag, pol, and env genes, which is characteristic of 
all retroviruses2.   Additionally, HIV-1 encodes the vif, vpr, vpu, nef, tat, and rev 
accessory genes, the products of which enhance virus replication and fitness within the 
human host3 (Figure 1.1).  HIV-1 is further classified as a lentivirus due to a long period 
of clinical latency that is observed after the acute infection4, 5 (discussed in greater detail 
below).  HIV-1 infects cells expressing its primary receptor CD4 and one of its co-
receptors, CXCR4 or CCR5 6-12  (Figure 1.2).  The primary cellular target of HIV-1 are 
CD4+ T cells13.  Following binding to the cell surface, fusion of the viral and cellular 
membranes occurs, releasing the viral genome into the cell cytoplasm14, 15.  At this point 
the HIV-1 ssRNA genome is reverse transcribPed into a double stranded cDNA provirus 
by the viral reverse transcriptase (RT) enzyme and is trafficked to the nucleus as part of 
the pre-integration complex (PIC)16, 17.  The viral integrase (IN) protein mediates proviral 
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integration into the cellular DNA18.  The virus’ ability to integrate into the cellular DNA 
allows it to persist for the life of the infected cell and to be replicated during normal 
cellular division.  Integrated virus can be latent where it is virtually undetectable or 
transcriptionally active and produce new viral particles19.  Viral mRNA transcripts and 
full-length genomes are generated by binding of the 5’ LTR promoter by the cellular 
transcription machinery.  Elongation of viral transcripts is enhanced by the HIV-encoded 
Tat protein20.  Subsequently, the newly synthesized viral transcripts are spliced and 
translated to generate each of the nine HIV-1 gene products.  Viral particles assemble at 
the plasma membrane with two copies of the ssRNA HIV-1 genome and several HIV-1 
proteins, including the Gag precursor polyprotein, envelope (Env), protease (PR), IN, RT, 
virion infectivity factor (Vif), negative factor (Nef) and viral protein R (Vpr)21.  Particles 
bud from the surface of the cell and mature, which involves PR cleavage of the Gag 
polyprotein into capsid (CA), matrix (MA) and nucleocapsid (NC) structural subunits22.  
The mature HIV-1 virions are infectious. 
HIV disease progression 
HIV disease occurs in a series of stages and ultimately leads to immune system 
destruction and death of the infected individual due to an inability to suppress 
opportunistic infections (reviewed in 23) (Figure 1.3).  The acute phase of infection is 
characterized by an initial spike in viremia that is limited by the cellular immune 
response (reviewed in 24).  However, unlike many viral infections, the immune response 
is unable to completely clear the infected cells due to virally encoded immune evasion 
strategies.  The remaining virus load level is known as the viral set point24 (Figure 1.3, 
black arrow).  Following the acute infection, patients infected with HIV have a stage of 
clinical latency that can last for several years and is characterized by normal CD4+ T cell 
counts and little detectable viremia4.   Over time HIV gradually weakens the immune 
system of the infected individual by killing CD4+ T cells24.  As CD4+ T cell numbers 
decline, virus replication increases, leading to an inability to control infections.  This 
leads to an increased susceptibility to opportunistic infections and acquired 
immunodeficiency syndrome (AIDS).  The inability of AIDS patients to clear these 
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infections ultimately results in the death of the individual.   
To limit viral replication and spread, highly active anti-retroviral therapies 
(HAART) have been developed to target stages in the viral life cycle25.  Although 
HAART is effective at preventing the spread of infection, long-lived HIV-infected 
cellular reservoirs remain unaffected by drug treatment25.  Failure of drug treatment is 
also common due to the acquisition of drug resistant mutations25.  Therefore, elimination 
of HIV from the body will likely require more than HAART alone. 
Cellular immune response to viral infections  
Cytotoxic T lymphocytes (CTLs) detect peptide antigens presented by major 
histocompatibility complex class I (MHC-I) proteins on the surface of cells26, 27.  MHC-I 
proteins are made of a human leukocyte antigen (HLA) α chain that is non-covalently 
linked to an invariant β2-microglobulin (β2M) light chain27.  The α chain folds into three 
domains: α1, α2 and α3 27.  The folding of the α1 and α2 domains forms a peptide-binding 
cleft that presents peptide antigens to responding CTLs while the α3 domain interacts 
with β2M and spans the plasma membrane27.  Humans encode six different MHC-I HLA 
genes, including HLA-A, -B, -C, -E, -F and -G26.  HLA-A, -B and -C proteins make up 
the classical MHC-I molecules that are highly polymorphic within the human population.  
According to current EMBL reports there are 739 different HLA-A, 1,268 different HLA-
B and 513 different HLA-C alleles within the human population28.  Each person 
expresses two HLA-A, -B and -C alleles (one per chromosome) that are likely different 
given the level of polymorphism.  HLA-E, -F and -G are termed MHC-IB molecules and 
are almost completely conserved26.  Short peptides derived from proteins expressed by 
the cell, including those of any intracellular pathogens, are presented to circulating CTLs 
by MHC-I molecules27.  CTLs express antigen-specific T cell receptors that distinguish 
which peptide-MHC-I complexes are foreign and lyse infected cells27. 
HIV-specific CTLs recognize infected cells, the earliest CTL responses detecting 
Nef and Env epitopes24.  However, the HIV Nef gene product selectively downmodulates 
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expression of the MHC-I allotypes HLA-A and –B, which limits this response29, 30.   Nef 
functions as an adapter protein by binding the cytoplasmic tail domains of HLA-A and -B 
molecules and linking them to the cellular adaptor protein 1 (AP-1), which redirects 
MHC-I molecules to a lysosomal degradation pathway31-33.  Therefore HIV-infected cells 
are not efficiently recognized by CTLs. 
Inhibiting the presentation of viral peptides to responding CTLs by 
downmodulating MHC-I is a common strategy employed by viruses that establish 
chronic infections34.  However, natural killer (NK) cells lyse cells with reduced MHC-I35.  
Whether NK cells lyse a target cell depends on a balance of inhibitory and activating 
signals35 (Figure 1.4).  NK cell signaling is mediated by inhibitory and activating 
receptors that recognize specific ligands on the surface of target cells and transmit a 
signal via immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor 
tyrosine-based activation motif (ITAM) containing molecules35.  Inhibitory receptors 
detect specific MHC-I allotypes and some non-MHC-I ligands; these receptors include 
the killer cell immunoglobulin-like receptors (KIR) with long cytoplasmic tail domains, 
the leukocyte immunoglobulin-like receptors (LILR) and the CD94-NKG2 C-type lectin 
receptors35.  Like MHC-I, there are several different allotypes of KIR that are expressed 
among the human population36.  However, their expression on NK cells within each 
person is variegated, as NK cells can express some or all of the KIRs encoded36.  HLA-C 
and -E molecules, which are resistant to Nef-mediated downmodulation, reduce NK cell 
recognition of HIV-infected cells by providing inhibitory signals to the responding NK 
cell37.  However, an effect of HIV on NK cell activating signals has not been studied. 
NK cell activation is mediated by receptors that recognize activating ligands 
expressed on the surface of target cells35.  There are two major families of NK cell 
activating receptors, the natural cytotoxicity receptors (NCRs) and the natural-killer 
group 2, member D (NKG2D) receptor; however some CD94-NKG2 and the KIRs with 
short cytoplasmic tail domains also transmit activating signals due to the presence of 
ITAM signals35.  In addition to these primary activating receptors, NK cells express a 
number of activating co-receptors that can stimulate lysis in conjugation with one of the 
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primary activating signals38.  Members of the co-receptors include the signaling 
lymphocyte activation molecule (SLAM) family of receptors and NKp80.  NK cell 
activating ligand expression can be induced during viral infection and cellular 
transformation.  Little is known about the ligands recognized by the NCRs, however 
NKG2D recognizes a number of distinct but structurally similar ligands39.  Members of 
the NKG2D ligands include MHC class I-related (MIC) A and B and members of the 
UL-16 binding protein (ULBP) and retinoic acid early transcript 1 (RAET1) protein 
families39.  NKG2D activating ligands are upregulated under conditions of cellular stress 
including DNA damage40, heat shock41-43, oxidative stress44, 45, histone deacetylase 
inhibition46, 47 and during T cell stimulation48, 49.  Infection by a number of viruses 
including CMV, HTLV, Adenovirus Ad5, Abelson murine leukemia virus (AMLV) and 
HIV have also been shown to stimulate NKG2D ligand expression50-54.  However many 
of these and other viruses encode specific mechanisms to limit the expression of NKG2D 
ligands55-61, suggesting the importance of limiting NK cell activation to evade NK cell 
recognition. 
NK cell response to HIV infection 
The role of NK cells in limiting HIV infection is best shown by studies of the 
allelic frequencies of HLA and KIR molecules among populations.  All HLA-B molecules 
express either the Bw4 or Bw6 serological epitope, which is determined based on the 
amino acids at positions 77-83 62.  HLA-B Bw4 molecules are recognized by the 
inhibitory KIR3DL1 (3DL1) receptor and thus inhibit NK cell lysis36.  Despite having 
roughly 97% homology to the extracellular portion of 3DL1, the activating KIR3DS1 
(3DS1) receptor does not recognize HLA-B Bw4 molecules63.  However, the expression 
of HLA-B Bw4 molecules with isoleucine at position 80 (HLA-B Bw4-80Ile) and 3DS1 
correlates with disease progression, where individuals expressing both Bw4-80Ile and 
3DS1 progressed to AIDS at a slower rate than those with either one or neither of these 
molecules64.  The resistance to HIV-infection observed in these individuals is likely 
explained by increased 3DS1 expression among Bw4+ individuals compared with Bw4- 
63.  Likewise, higher expression of NK cell activation markers, including 3DS1, was 
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observed in a cohort of HIV-exposed uninfected individuals compared with HIV-infected 
controls65, suggesting that NK cell activation potential may confer protection to HIV. 
HIV-1 viremia affects NK cell receptor expression and the frequency of NK cell 
subpopulations.  NK cells from HIV-infected individuals express decreased levels of the 
activating NCRs NKp30, NKp44, and NKp46 and are less cytotoxic than those from 
healthy donors66, 67.   
NK cells are divided into two main subtypes based on their neural cell adhesion 
molecule (CD56) and IgG Fc receptor (CD16) surface expression68.  CD56dim CD16+ NK 
cells are highly cytotoxic, whereas CD56bright CD16low NK cells are less cytotoxic and 
serve a regulatory function68.  In a healthy individual the vast majority of circulating NK 
cells are the cytotoxic CD56dim subset68.  However, HIV viremic individuals have an 
outgrowth of a rare and non-cytotoxic CD56-CD16+KIR+ population of NK cells69, 70.  
This outgrowth of CD56-CD16+KIR+ cells was not observed in HIV-infected individuals 
undergoing HAART67, indicating active virus replication is required.  The total number 
of NK cells expand during acute HIV infection and then retract to normal levels during 
chronic infection71.  The expansion during acute HIV infection is observed due to 
increased CD56dimCD16+ NK cells that decrease to normal levels during chronic 
infection71.  However, the percentage of CD56brightCD16low NK cells decreases and 
dysfunctional CD56-CD16+ cells expand during chronic infection71.  Because these 
changes in the NK cell population occurs as infection progresses, this dissertation focuses 
on understanding the susceptibility of HIV-infected cells to healthy NK cells to shed light 
upon the earliest infection events and analyzes HIV’s effects on NKG2D ligand 
expression. 
APOBEC/AID cytidine deaminases 
NKG2D ligands are upregulated under conditions of cellular stress.  One form of 
stress that cells regularly encounter is DNA damage.  The RNA base uracil (U) is found 
in cellular DNA via the misincorporation of dUTP or deamination of cytidine (C) 
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residues and plays an important role in adaptive and innate immune responses (reviewed 
in 72).  The level of misincorporation depends on the concentration of cytosolic dUTP; it 
is estimated that 104 dUTP residues are incorporated into cellular DNA during 
replication73.  Because uracil incorporation can be mutagenic, cells express dUTPase and 
uracil DNA glycosylase (UDG) enzymes to limit the pool of dUTP and remove 
incorporated uracil residues, respectively.  There are several UDG enzymes that have 
overlapping function.  They include mitochondrial UNG1, nuclear UNG2, nuclear single 
strand selective mono-functional uracil-DNA glycosylase (SMUG1), thymine/uracil 
mismatch DNA glycosylase (TDG), and methyl binding domain 4 protein (MBD4)74.  
UNG and SMUG1 typically remove uracil from single stranded DNA (ssDNA) but also 
have enzymatic activity against uraciliated double stranded DNA (dsDNA)74.  TDG and 
MBD4 serve to remove uracil from dsDNA resulting from dUTP misincorporation74.  
The mechanism of nucleotide removal and DNA repair is discussed in greater detail in 
the next section. 
Cytidine deamination occurs either spontaneously or is mediated by cellular 
cytidine deaminases72.  The apolipoprotein B editing complex (APOBEC) family of 
cytidine deaminases is important in innate and adaptive immune responses and includes 
activation induced deaminase (AID) and APOBEC3 isoforms75.  AID has been shown in 
B cells to initiate antibody somatic hypermutation (SHM) and class switch recombination 
(CSR) in lymph node germinal centers76, 77.  However, AID is ectopically upregulated in 
retrovirally infected B cells through an ill-defined mechanism involving the transcription 
factor NFκB52, 78.  The DNA damage induced as a result of AID expression induces 
NKG2D ligand expression52.  It is unclear however, whether the DNA damage signal 
induced by AID expression that leads to NKG2D ligand expression is of cellular or viral 
origin. 
Several of the APOBEC3 isoforms have been shown to be important intrinsic 
factors in limiting retroviral infection and endogenous retroelement translocation79-84.  
The APOBEC3G (A3G) and APOBEC3F (A3F) isoforms (A3G being the most anti-
viral) are important factors for limiting HIV-1 replication85, 86.  A3G has both deaminase-
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dependent and independent mechanisms of inhibiting HIV infection.  Firstly, A3G is 
incorporated into budding virions and deaminates the viral genome during the first strand 
cDNA synthesis step of reverse transcription87-89.  This results in the accumulation of G-
to-A hypermutations of the viral genome and production of defective virions.  A3G also 
inhibits the completion of reverse transcription, which results in the production of 
abnormal HIV cDNA fragments that are unable to integrate90.  Deaminase domain 
mutants also limit HIV-1 replication91, 92, which revealed a second deaminase-
independent mechanism of A3G inhibition.  This mechanism has been attributed to 
A3G’s ability to inhibit translocation of RT along template RNA93.  More recently, a role 
for A3G in enhancing CTL recognition of HIV-infected cells has been revealed, which 
suggested that the anti-viral effects of A3G may extend beyond inhibiting replication94. 
A3G expression varies from one cell type to another and exists in RNA-bound 
high molecular mass (HMM) and unbound low molecular mass (LMM) forms95.  
Analysis of the enzymatic activity of these forms revealed that the HMM form was less 
catalytically active than the LMM form96.  Catalytic activity could however be restored 
with RNase digestion of the A3G-ribonucleoprotein (RNP) complex96.  Furthermore, the 
abundance of each A3G form differed among resting and activated T cells and correlated 
with HIV infectivity, where activated T cells predominately expressed HMM A3G and 
resting T cells predominately expressed LMM A3G96.  However, enzymatically active 
A3G must also be expressed in activated T cells as A3G-dependent hypermutation of the 
HIV-1 genome is observed in virus derived from these cells.   
Cells detect pathogen associated molecular patterns (PAMPs) via toll-like 
receptors (TLR), nucleotide oligomerization domain-like receptors (NLR), and retinoic 
acid-inducible gene I-like helicases (RLH)97-99.  In the case of viral infections, the most 
common PAMP is viral nucleic acid found either in endosomal compartments or in the 
cytoplasm (reviewed in 100).  The recognition of these pathogen markers leads to 
proinflammatory cytokine and type I interferon (IFN) secretion, which modulates anti-
viral immune responses.  Several of these cytokines, including IFN-α, IFN-γ, IL-2 and 
IL-15, have been shown to upregulate A3G expression101-103.  Additionally, it was 
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recently reported that Influenza virus RNA induces A3G expression104 and type I IFNs 
produced by TLR3 stimulated dendritic cells upregulate expression of a LMM form of 
A3G105.  Thus, cells have the capacity to upregulate the intrinsic antiviral factor A3G in 
response to viral infections. 
To limit the detrimental effects of A3G packaging into viral particles, the HIV-1 
vif gene product targets A3G for proteasomal degradation in virus producing cells87, 106, 
107 (Figure 1.5).  Vif functions as an adaptor protein to link A3G to a 
Cullin5/ElonginB/ElonginC E3 ubiquitin ligase complex108.  This leads to poly-
ubiquitination of A3G, targeting it to the proteasome for degradation109-111.  However, 
Vif’s effects on A3G are not absolute, as hypermutated genomes have been isolated from 
individuals infected with full-length HIV-1112, 113.  In fact, minimal mutations induced by 
A3G are thought to benefit HIV-1 by promoting the acquisition of drug resistance114, 115.   
Cellular DNA damage response and NKG2D ligand expression 
DNA mutations generated by nucleotide misincorporation during replication or 
breaks induced by environmental stress are commonly encountered by cells (reviewed 
by116).   Limiting the detrimental effects of DNA damage is vital for cells to maintain 
genomic integrity.  Cells achieve this stability through intricate mechanisms of arresting 
the cell cycle to halt DNA replication and repair damaged DNA (discussed below).  In 
the event of irreparable damage, these same mechanisms trigger apoptosis in the 
damaged cell to prevent the passage of mutations to daughter cells.  
As stated previously, uracil residues are incorporated in DNA as a result of dUTP 
misincorporation and cytidine deamination.  Cells detect incorporated uracils and remove 
them via the base excision repair (BER) mechanism during S phase of the cell cycle 
(Figure 1.6) (reviewed by 117).  Uracils are first removed by the UDG enzymes UNG2, 
SMUG1, TDG and MBD4, resulting in an abasic site (AP-site).  Because replication 
through the AP-site could potentially be mutagenic, AP-endonuclease 1 (APE1) cleaves 
the residual deoxyribosephosphate (dRP) and the DNA is repaired by short patch or long 
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patch mechanisms.  In short patch repair, the dRP is removed and the missing nucleotide 
is filled in by DNA polymerase β (Polβ) and the ends are joined by DNA ligase.  In 
instances where the dRP is not removed by Polβ, a long patch repair mechanism is used.  
In long patch repair, DNA polymerase δ/ε adds 2-8 nucleotides, which results in the 
displacement of a DNA “flap”.  This flap is then cleaved by flap-endonuclease 1 (FEN1) 
and the DNA is ligated.  In the event of hyperuracilation of the genome, DNA 
fragmentation may result due to the removal of uracils located close to one another on 
opposite DNA strands118.  These DNA fragments may activate DNA damage responses 
due to exposed stretches of ssDNA or free dsDNA ends (or double strand breaks, DSBs). 
Exposed stretches of ssDNA are quickly stabilized by replication protein A (RPA) 
(Figure 1.7a) (reviewed in 119).  The RPA coated ssDNA then recruits the RAD9– RAD1–
HUS1 (also known as 9-1-1) protein complex, the ataxia–telangiectasia mutated and 
RAD3-related (ATR) kinase, and ATR interacting protein (ATRIP) to the junction of the 
ssDNA and the exposed 5’ primer.  Loading of the 9-1-1 complex to the site of DNA 
damage leads to the recruitment of topoisomerase-binding protein-1 (TOPBP1), which 
then binds to and phosphorylates ATR.  Activated ATR then phosphorylates a number of 
targets including checkpoint kinase-1 (Chk1) and the histone H2AX.  These activated 
effectors ultimately lead to cell cycle arrest, replication fork stability and removal of the 
mutated DNA. 
DSBs are encountered less frequently by cells yet have highly deleterious 
potential.  In response to a DNA DSB, mammalian cells activate a signaling cascade 
aimed at recognizing the site of damage, propagating the signal and initiating repair of 
the damage.  Central in the early events of DSB repair is the MRE11-RAD50-NBS1 
(MRN) complex, which surveys the genome and associates at the ends of dsDNA breaks 
(Figure 1.7b) (reviewed in 120).  Once at the site of DNA damage, the MRN complex 
activates the ataxia–telangiectasia mutated (ATM) kinase.  ATM is normally found in the 
nucleus as a dimer in association with protein phosphatase 2A (PP2A).  Upon activation, 
PP2A dissociates and ATM monomers trans-autophosphorylate and associate at the site 
of damage121.  Phosphorylated ATM then phosphorylates the histone H2AX (the 
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phosphorylated form referred to as γH2AX), which serves as a scaffold to recruit 
downstream repair proteins to the site of damage.  Concurrently, ATM phosphorylates 
checkpoint kinase-2 (Chk2), which inhibits cell cycle progression to allow for repair of 
the damaged DNA.  Cells undergoing replication most commonly repair DSBs through a 
mechanism of homologous recombination (HR) with the sister chromatid serving as 
template122.  Quiescent cells typically repair DSBs by resecting the DNA ends and 
ligating them to one another via a mechanism of non-homologous end joining (NHEJ)122.  
The resected ends generate a stretch of ssDNA that can be recognized by RPA and 
activate ATR.123, 124 
Although its role in HIV-1 infection remains unclear, a consistent phenotype of 
HIV-1 Vpr expression is arrest of the cell cycle at the G2/M transition125, 126.  Vpr 
expression activates the canonical ATR response, indicated by the accumulation of DNA 
repair foci containing γH2AX and RPA and the subsequent activation of Chk1127.  Vpr 
has also been shown to activate ATM, indicated by γH2AX expression and Chk2 
phosphorylation128.  Vpr functions as an adaptor protein, linking cellular targets to a viral 
protein R binding protein (VprBP or DCAF1), damaged DNA binding protein 1 (DDB1) 
and cullin 4A (Cul4A) E3 ubiquitin ligase complex129-131.  Although the ability of Vpr to 
colocalize with ubiquitinated proteins and target them for proteasomal degradation is 
necessary for γH2AX focus formation and cell cycle arrest132, the repertoire of proteins 
targeted by Vpr is incompletely defined.  Identification of the protein targets will allow 
for further characterization of the Vpr-mediated cell cycle arrest and lead to a greater 
understanding of the role of Vpr in HIV-1 infection.  It has recently been shown that Vpr-
mediated activation of an ATR response induces the expression of NKG2D activating 
ligands133, 134, which may be a consequence of degrading one or many cellular targets. 
Although their degradation does not appear to explain the G2/M cell cycle arrest 
phenotype, several cellular targets of Vpr have been identified.  Many of the proteins 
identified are part of cellular DNA repair responses, including UNG2, SMUG1 and 
HHR23A135-139.  As stated previously, UNG2 and SMUG1 are UDG enzymes that 
remove uracil from DNA as a result of misincorporation or cytidine deamination.  
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HHR23A is the human homolog of the yeast Rad23 protein and is part of the nucleotide 
excision repair (NER) pathway, detecting DNA damage as a result of UV irradiation140.  
In the absence of Vpr, UNG2 is incorporated into newly formed HIV-1 virions through 
an interaction with integrase and is thought to limit HIV infection by degrading the 
genome141.  Consistent with this hypothesis, it has been shown that Vpr partially rescues 
HIV-1 infectivity in the absence of Vif by reducing the detrimental effects of A3G139 and 
that virion-associated UNG2 degrades A3G-edited HIV DNA142.  Mutating the 
tryptophan at position 54 of Vpr disrupts UNG2 binding and partially reverses Vpr’s 
ability to enhance infectivity135, 143.  However, it was shown that HIV replication is 
unaffected by endogenous levels of UNG2 either in the presence or absence of A3G144, 
which suggests A3G’s capacity to inhibit HIV infectivity is not solely due to degradation 
of the genome. 
Summary of dissertation 
This dissertation improves our understanding of HIV’s ability to evade immune 
recognition by NK cells.  Although it is clear that HLA-C and –E molecules are 
unaffected by Nef and inhibit NK cell lysis37, the role of NK cell activation in HIV 
infection is less defined.  Ligands recognized by the NK cell activating receptor NKG2D 
are upregulated under conditions of cellular stress, including viral infection and DNA 
damage.  Indeed the DNA damage response induced by the HIV-1 Vpr protein 
upregulates NKG2D ligand expression133, 134.  However, I show that NKG2D ligand 
expression is limiting in HIV infection due functions of the Vif and Nef proteins.  
One form of genotoxic stress that cells regularly encounter is the presence of 
uracil in their DNA, which occurs by misincorporation or cytidine deamination.  Since 
the cytidine deaminase AID activates the DNA damage response and induces NKG2D 
ligand expression52, it seemed likely that A3G expression would have a similar outcome.  
In fact, I find in this dissertation that A3G expression activates a DNA damage response 
and upregulates NKG2D ligands.  However, maximal NKG2D ligand expression in HIV-
infected T cells requires Vpr expression, which I attribute to Vpr’s effects on the 
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expression of the DNA repair proteins UNG2 and HHR23A.  Therefore, the data 
presented in this dissertation suggest that A3G induces DNA damage that is stabilized by 
Vpr-mediated degradation of UNG2 and HHR23A.   
This dissertation is organized into two additional chapters and two appendices. 
Chapter 2, which has been submitted for publication, analyzes the modulation of NKG2D 
ligands and NK cell recognition of HIV-infected primary T cells.  It also further 
investigates the upregulation of NKG2D ligands and activation of the DNA damage 
response by A3G.  In Chapter 3 I discuss these findings in detail and offer several 
avenues of future investigation.  Preliminary evidence is presented in Appendix 1 
supporting the hypothesis that the degradation of DNA repair enzymes by Vpr enhances 
NKG2D ligand expression.  While much of this dissertation is focused on the inhibition 
of NKG2D ligand expression by Vif, Appendix 2 presents preliminary data on the 
mechanism of Nef-mediated NKG2D ligand inhibition.  
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Figure 1.1: HIV-1 genome 





Figure 1.2: HIV-1 Replication 
1. Receptor binding and membrane fusion.  2. Reverse transcription.  3. Integration.  4. 
Transcription and genome synthesis.  5. Translation.  6. Particle assembly and budding.  








Figure 1.3: Natural course of HIV-1 infection 
Plot of CD4+ T cells/mm3 (black circles) and plasma viremia titer (white squares) versus 






Figure 1.4: Natural killer cell recognition 
NK cell inhibitory receptors transmit signals that inhibit NK cell lysis (red arrow) and 





Figure 1.5: HIV-1 Vif degrades APOBEC3G to limit virion incorporation 
APOBEC3G is incorporated into budding virions in the absence of HIV-1 Vif and 
inhibits infection of the target cell by inducing G to A hypermutation and inhibiting RT 
elongation.  HIV-1 Vif targets A3G for proteasomal degradation by linking it to the 
















Figure 1.6: Base excision repair pathway 
Simplified model of short patch and long patch base excision repair of uracil 
incorporation.  Incorporated uracils are removed by uracil DNA glycosylase (UDG) 
enzymes and result in the formation of an abasic (AP) site.  The AP site is repaired by 
cleavage of the DNA backbone by AP-endonuclease 1 (APE-1), which activates short 
patch or long patch repair mechanisms.  DNA Polymerase β (Polβ) removes the abasic 
nucleotide and replaces it with the correct base in short patch repair.  DNA Polymerase 
δ/ε (Polδ/ε) adds a stretch of 2-8 nucleotides in long patch repair, which displaces a flap 









Figure 1.7: ATR and ATM DNA damage responses 
(a) Stretches of ssDNA are stabilized by replication protein A (RPA), which allows for 
the recruitment of several effector proteins to initiate repair.  The ATR kinase is integral 
to this response and is phosphorylated by TOPBP1 at the site of DNA damage.  Activated 
ATR can then phosphorylate the histone H2AX and Chk1.  Phosphorylated Chk1 inhibits 
cell cycle progression and allows for repair of the damaged DNA.  (b) The free ends of a 
dsDNA break are bound by the MRN complex of proteins, which then recruits 
phosphorylated ATM monomers to the site of DNA damage.  ATM then phosphorylates 
H2AX, which serves as a scaffold to recruit additional effector proteins to the site of 
damage and to amplify the response.  Activated ATM phosphorylates Chk2, which 





Figure 1.7: ATR and ATM DNA damage responses 
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Chapter 2  
The antiviral factor APOBEC3G enhances natural killer cell recognition of HIV-
infected primary T cells 
Abstract  
APOBEC3G (A3G) is an intrinsic inhibitor of human immunodeficiency virus 
(HIV) replication, which causes G-to-A hypermutations and inhibition of viral genome 
synthesis.  HIV counteracts A3G through the activity of viral infectivity factor (Vif), 
which degrades A3G.  Here, we show that A3G expression activates DNA damage 
response pathways and upregulates NK cell activating ligand expression.  Vif mitigates 
these effects of A3G and reduces NK cell lysis.  In HIV-infected cells, A3G-dependent 
upregulation of NK cell activating ligands and the DNA damage response also requires 
HIV viral protein R (Vpr).  Our results reveal that A3G acts not only as an antiviral factor 
but also as an activator of the NK cell response. 
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Introduction 
Following exposure to HIV, the acute phase of infection is characterized by high 
viral loads, which are counteracted by a rapid immune response1.  The first line of 
defense against viral infections is the innate immune system, which uses pattern 
recognition receptors to detect pathogen associated molecular patterns.  This response 
leads to cytokine secretion, which increases the expression of innate immune factors such 
as A3G that limit viral replication and spread2.  Some studies have reported that induction 
of A3G expression can be regulated by IFN-α, IFN-γ and IL-22-4. 
A3G is a member of a family of cytidine deaminases known as apolipoprotein B 
editing complex (APOBEC) proteins.  One of these family members, activation-induced 
cytidine deaminase (AID) has important functions in both innate and adaptive immunity.  
AID edits B cell receptors and promotes class switching5.  AID expression is upregulated 
in virally infected cells and has been shown to promote the expression of natural killer 
(NK) cell activating ligands by inducing the cellular DNA damage response6, 7.  In 
addition to inhibiting HIV, members of the APOBEC3 family inhibit DNA viruses, 
endogenous retroviruses, and LINE-1 retrotransposition8-13.  
The mechanism by which A3G inhibits HIV replication is probably twofold.  
Firstly, A3G is packaged into HIV particles and deaminates C residues to U in the minus 
strand of the virus during first strand cDNA synthesis14-16.  This editing leads to G to A 
hypermutation in the plus strand, which inactivates the virus.  Secondly, a deaminase-
independent mechanism of A3G inhibition has been revealed by the finding that A3G 
deaminase domain mutants also inhibit HIV infection17.  This mechanism has recently 
been attributed to an ability of A3G and A3F to inhibit the translocation of reverse 
transcriptase along template RNA18.   
The viral infectivity factor (Vif) from HIV-1 counteracts the inhibition of viral 
replication by targeting A3G for proteasomal degradation, thus reducing the amount of 
A3G incorporated into virus particles19, 20.  However, the action of Vif is not absolute and 
hypermutated viral genomes have been isolated from individuals harboring full-length 
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HIV-121, 22.   These sub-lethal mutations may influence HIV-1 evolution and promote the 
acquisition of drug resistance23. 
HIV-1–specific CD8+ cytotoxic T lymphocytes (CTLs) are involved in the 
decrease of viremia during acute infection and chronic stages of the disease24.  Despite 
this CTL response, most infected individuals control viremia poorly in the absence of 
antiviral treatment.  Several cellular and viral factors contribute to the failure of the 
immune system to control HIV-11.  CTLs recognize peptides derived from exogenous or 
endogenous antigens presented by MHC class I molecules (MHC-I).  One key factor, 
HIV Nef, protects HIV-infected cells from CTL recognition by disrupting antigen 
presentation by MHC-I25.  Viral effects on MHC-I antigen presentation however may 
lead to enhanced recognition by NK cells, which are normally inhibited by MHC-I via 
the signaling of NK cell inhibitory receptors (reviewed in 26).  Additionally, viral 
infection can upregulate expression of NK cell activating ligands, which enhance NK cell 
recognition and target cell lysis.   Upregulation of NKG2D ligands has been linked to 
expression of the HIV Vpr protein via its capacity to activate the DNA damage response 
pathway as measured by activation of the ATR kinase27.  However, HIV infected cells are 
not efficiently recognized by NK cells28, 29. 
Here, we examined the role of A3G in recognition of HIV-infected cells by NK 
cells.  We first studied NK cell recognition of full-length and Vif mutant HIV isolates.  
We then analyzed the role of A3G in the upregulation of NK cell activating ligands.  
Finally, we examined the role of the DNA damage response in linking viral infection to 
the cellular immune response.  Altogether, our results uncover a capacity of A3G to 
activate the DNA damage response pathway and to upregulate NKG2D ligands.  A3G 
expression enhances the ability of HIV-infected cells to activate NK cells.  Therefore, 
A3G cytidine deaminase acts as an intrinsic antiviral factor not only by disrupting viral 




HIV-infected primary T cells are resistant to NK cell recognition unless NKG2D 
ligand is overexpressed. 
HIV-1 Nef protects infected primary T cells from CTL recognition by 
downmodulating surface MHC-I expression25, 30.  Although this activity of Nef provides 
an explanation for how HIV evades CTLs, the presence of low MHC-I levels also raises 
questions about whether infected cells become targets of natural killer (NK) cells.  
Normally, MHC-I molecules send inhibitory signals to NK cells that block the release of 
cytotoxic factors such as perforin and granzymes.  A reduction in inhibitory signals 
through Nef-mediated MHC-I downmodulation may increase the sensitivity of infected 
cells to NK cell killing.  To examine this possibility, we used a previously described flow 
cytometric killing assay25, 31 to assess recognition of HIV-infected T lymphocytes by 
autologous NK cells. 
In this assay system, target cells pre-labeled with CFSE are incubated with media 
or unlabeled, highly purified, autologous NK cells.  Immediately afterward, the cell 
mixture is stained with antibodies directed against the NK cell markers, CD16 and CD56 
as well as the vital dye 7-AAD, to discriminate live and dead cells.  The number of 
7AAD-negative, CFSE-positive cells is then scored as a function of a defined number of 
inert counting beads that are added just prior to flow cytometric analysis.  When this 
assay system was tested using the highly sensitive K562 cells, which lack MHC-I and 
express high levels of NK cell activating ligands, we were able to demonstrate very 
efficient loss of living CFSE+ target cells with the addition of primary NK cells (Figure 
2.1).  
To assess NK cell lysis of HIV-infected primary T lymphocytes, we infected cells 
with HIV expressing a GFP reporter inserted within env to distinguish infected from 
uninfected cells (Figure 2.2a).  On day two of infection, autologous NK cells were mixed 
with the infected cells for a four-hour incubation and then analyzed to detect NK cell 
lysis as described for Figure 2.1.  We found that a high fraction of HIV-infected primary 
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T lymphocytes survived treatment with autologous NK cells, whereas K562 cells were 
completely killed (Figure 2.2b and c).  At the highest effector to target cell ratio tested, 
47% of the HIV-infected primary T lymphocytes survived, compared with <1% survival 
of K562 cells (Figure 2.2c).   
Because NK cell lysis depends on a balance of inhibitory and activating signals, 
we determined the relative contributions of NK cell activating ligand expression and 
residual MHC-I expression on the recognition of HIV-infected T lymphocytes by NK 
cells.  To test this, we constructed an HIV genome that overexpressed the NKG2D 
activating ligand, ULBP1 (NL-GIulbp1+) plus or minus a full-length nef open reading 
frame (Figure 2.2a).  Primary T cells infected with NL-GIulbp1+ expressed roughly 40-
fold more ULBP1 on their surface compared to control infected cells (Figure 2.2d).  We 
found that ULBP1 overexpression decreased the survival of HIV-infected cells 
approximately ten-fold suggesting that NKG2D activating factors were normally a 
limiting factor for NK cell lysis of HIV-infected primary T cells (47% survival versus 
4.8% survival at the highest effector:target cell ratio; Figure 2.2b, right panels and 
quantified in Figure 2.2c). 
We also examined NK cell recognition of infected, Nef-negative cells that had 
normal MHC-I expression levels.  Interestingly, these cells were substantially more 
sensitive to NK cell lysis than mock treated cells (45% survival compared to 85% at a 5:1 
effector to target cell ratio), which suggested that HIV infection did activate NK cell lysis 
even without MHC-I downmodulation (Figure 2.3a and b).  These data are consistent 
with prior reports that HIV infection upregulates NKG2D ligands32, 33.  However, 
overexpression of NK cell activating ligands by infection with NL-GIulbp1+nef – further 
increased killing and resulted in loss of most of the remaining cells.  
Vif downmodulates NKG2D activating ligands.   
To better understand what determines the levels of NKG2D activating ligands on 
HIV-infected primary T cells, we measured NKG2D activating ligand expression on cells 
infected with full-length HIV (NL-PI) or HIV mutated to disrupt the expression of each 
accessory protein (Figure 2.4a).  To assay for total NKG2D ligand upregulation, cells 
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were stained with recombinant human NKG2Dfc.  As shown in Figure 2.4b and c, HIV 
that encoded all of the accessory proteins (NL-PI, black histogram) induced the 
expression of NKG2D ligands in primary T cells by an average of 3.3-fold compared to 
mock-treated controls.  However, expression was further increased in the absence of Vif  
(4.1-fold, p < 0.02) or Nef (3.9-fold, p < 0.02), demonstrating that Vif limited NKG2D 
ligand expression and confirming a previous report that Nef reduced NKG2D ligand 
expression34.  This effect was not additive in the double mutant, vif –nef – (mean 3.9-fold 
expression relative to mock treated; p < 0.05 compared to NL-PI), suggesting that Vif and 
Nef were acting on the same pathway.    
In contrast, NKG2D ligand expression was nearly the same as mock–infected 
cells in the absence of Vpr expression and was 3.4-fold less than NL-PI-infected cells  (p 
< 0.002 compared to NL-PI, Figure 2.4b and c), confirming that Vpr expression was 
required for HIV-mediated NKG2D ligand upregulation27.  Furthermore, examination of 
doubly mutated genomes revealed that all of the additional ligand upregulation observed 
in the absence of Vif and Nef was also dependent on Vpr expression (Figure 2.5a and b).  
Thus, both Vif and Nef counteracted Vpr-dependent NKG2D ligand upregulation, again 
suggesting that Vif and Nef were acting on the same pathway.  
NKG2D ligand modulation correlates with NK cell susceptibility.   
To determine whether the ability of Vif to counteract NKG2D ligand upregulation 
was functionally relevant, we asked whether Vif expression affected NK cell lysis of 
infected cells.  As shown in Figure 2.6, an analysis of infected cells from five 
independent donors revealed that cells lacking Vif were significantly more sensitive to 
NK cell recognition than full-length HIV controls in a four hour cytotoxicity assay (mean 
survival 60% and 66% for full-length compared with 38% and 45% for infected cells 
lacking Vif, at effector to target ratios 5:1 and 2:1, respectively).   Thus, the ability of Vif 
to limit NKG2D ligand expression resulted in increased survival of HIV infected T cells. 
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NK cell lysis of HIV infected primary T cells depends on both MHC-I and NKG2D 
activating ligands.   
MHC-I allotypes unaffected by Nef (HLA-C and HLA-E) have been shown to 
inhibit NK cell lysis28.  To separate the inhibitory effects of residual MHC–I on NK cell 
recognition from the activating effects of ligand expression, we developed an assay 
system where surface expression of all MHC-I allotypes was reduced by knocking down 
β2-microglobulin (β2M).  In cells in which β2M expression has been knocked-down, the 
MHC-I heavy chains are expressed poorly and accumulate in the endoplasmic 
reticulum35.  As shown in Figure 2.7, β2M knockdown reduced the surface expression of 
HLA-A2, HLA-B57, HLA-Cw4 and HLA-E molecules in a T cell line.  In primary T 
lymphocytes, β2M knockdown resulted in a 10-fold reduction of total MHC-I surface 
expression levels.   We used these cells to assess NK cell lysis of T cells with moderately 
reduced MHC-I levels (Figure 2.8a and b, gray boxes).  We found that non-selective 
reduction of MHC-I surface expression by β2M knockdown alone resulted in a decrease 
in cell survival compared to control shRNA infected cells and was similar to that 
observed in full-length HIV infected cells (Figure 2.8c, compare black triangles 100%, 
black squares 54% and white triangles 64%).   Non-selective reduction of MHC-I in full-
length HIV infected cells led to a 22% decrease in survival at the highest E:T tested when 
compared to HIV infection alone (Figure 2.8c, from 64% to 42%, compare white 
triangles and white squares), which is consistent with previous reports that residual 
MHC-I inhibits NK cell lysis28.  However, the survival decreased an additional 22% at 
the highest E:T tested in the absence of Nef when compared to full-length HIV (Figure 
2.8c, from 42% to 20%, compare gray squares to white squares), consistent with the 
effect of Nef on NKG2D ligands (Figure 2.4c).     
We then examined whether expression of Vpr was responsible for the increased 
sensitivity of infected versus uninfected cells, as NKG2D ligand expression is Vpr-
dependent in HIV infection (Figure 2.4c).  For these experiments, MHC-I was reduced 
using the shβ2M system so that NK cell killing could be assessed in the absence of Nef-
mediated selective MHC-I downmodulation and without Nef’s effects on NKG2D ligand 
expression.   Furthermore, cells were infected with NL-PI vif -vpr +nef - to yield maximal 
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NKG2D ligand expression.  These were compared to cells infected with NL-PI vif +vpr -
nef -, which expressed minimum NKG2D ligands and whose MHC-I was reduced by β2M 
knockdown alone.  As shown in Figure 2.9a and b, we did indeed note decreased target 
cell survival of infected (PLAP+) versus uninfected (PLAP–) cells with reduced MHC-I 
when Vpr (but not Vif or Nef) was expressed (Figure 2.9b, from 51% to 35%, compare 
black squares to white squares).  In contrast, there was no significant decrease in cell 
survival in the absence of Vpr compared with uninfected cells with low MHC-I (Figure 
2.9a and b, compare black squares and gray squares, 51% and 59%, respectively).    
To determine whether the increased susceptibility to NK cells observed in 
infected cells expressing Vpr was due to NKG2D ligand upregulation, we asked whether 
this effect could be blocked by an anti-NKG2D antibody.  As shown in Figure 2.9c, Vpr-
expressing infected cells were more susceptible to NK cell lysis than uninfected cells 
with similarly reduced MHC-I (32% and 70% survival for infected and uninfected with 
IgG control antibody, respectively).  However, in the presence of anti-NKG2D antibody, 
survival of Vpr-expressing, infected cells increased to that of uninfected cells (70% 
survival, Figure 2.9c, upper panel).  In contrast, infected cells lacking Vpr survived better 
when co-incubated with NK cells (55% versus 32% survival for Vpr-expressing, Figure 
2.9c, upper panel).  Anti-NKG2D antibody further increased the survival of Vpr-negative 
infected cells (81% survival, Figure 2.9c, upper panel).  This antibody also increased the 
survival of uninfected PHA-activated primary T lymphocyte control cells, which we and 
others have noted express low levels of NKG2D ligands [36 and data not shown].   As 
expected, for all conditions, the susceptibility of the cells to NK cell lysis was dependent 
on reduction of MHC-I expression via expression of shβ2M and only minimal amounts of 
lysis were observed when cells were treated with the negative control shRNA (Figure 
2.9c, lower panel). 
A3G upregulates NKG2D ligands.   
The cytidine deaminase A3G is an intrinsic inhibitor of HIV infection, causing 
hypermutation in the viral genome.  The HIV Vif protein counteracts these protective 
effects by targeting A3G for degradation.  Given Vif’s ability to limit NKG2D ligand 
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expression and its role in degrading A3G, we asked whether A3G expression influenced 
NKG2D ligands.  A3G expression has been shown to be upregulated by IFN-α, IFN-γ 
and IL-23, 4.  However, treatment of PBMCs with IFN did not result in increased NKG2D 
ligand expression (data not shown).  Interestingly, we observed that when CD56–CD8– 
PBMCs were incubated with conditioned supernatant from CD8– PBMC cultures the 
surface expression of NKG2D ligands increased (Figure 2.10).  Mock-infected cells 
treated with conditioned supernatant for 2 days expressed 2.3-fold higher NKG2D 
ligands than control treated cells (As shown in Figure 2.10b, left panels).  Further 
analysis of the mock-infected supernatant treated cells revealed that there was a range of 
total A3G expression among donors and that incubation with conditioned supernatant 
increased A3G expression within each donor (Figure 2.10c).  Interestingly, the relative 
difference in A3G among donors correlated strongly with increased NKG2D ligand 
expression (Figure 2.10d).  
Furthermore, cells infected with a Vif-deficient HIV also expressed increased 
NKG2D ligands expression when cultured in conditioned supernatant (Figure 2.10b, 40% 
increase compared with control media and 7-fold increase compared with mock–infected 
cells with control media).  Western blot analysis revealed that HIV containing 293T cell 
supernatant dramatically stimulated expression of A3G and that this increase was not 
secondary to expression of Vpr (Figure 2.11a).  The magnitude of the increase varied 
across donors but was usually at least two-fold and was sometimes greater than ten-fold, 
especially in viruses lacking Vif (Figure 2.11b) or containing a mutant Vif  (Vif Y44A ) 
that was unable to bind A3G37.  
Overall, we noted a strong correlation between the induction of NKG2D ligand 
expression and A3G levels for both infected and uninfected cells and a significant 
additional effect of infection  (Figure 2.11c, mock R2 = 0.66, NL-PIvif – R2 = 0.84, 
regression lines significantly different p < 0.0001).  These data support the model that 
A3G expression determines the extent to which NKG2D ligands are upregulated in 
infected cells.   
Cells infected with a Vif Y44A HIV, had similar NKG2D ligand expression as 
Vif-deficient virus, indicating that Vif’s ability to limit NKG2D ligands was dependent 
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on A3G binding (Figure 2.11d, donors independent of Figure 2.4, NL-PIvif – p = 0.003, 
NL-PI Vif Y44A p = 0.001 when compared to NL-PI).  These data provide direct 
evidence that A3G expression affects NKG2D ligand expression. 
In a second cohort of donors we again observed that Vpr expression was also 
required for HIV-induced NKG2D ligand expression because levels of ligand were 
similar to mock-infected in NL-PIvif –vpr– infected cells (Figure 2.11d and Figure 2.5b, 
NL-PIvif –vpr – p = 0.008 when compared to NL-PI).  Thus both A3G and Vpr contribute 
to maximal ligand expression in HIV-infected primary T lymphocytes. 
A3G activates the DNA damage response in HIV infected primary T cells.   
The cellular response to DNA damage results in phosphorylation of the cyclin-
dependent kinases, ATR or ATM, leading to cell cycle arrest and repair of the damaged 
DNA (reviewed by 38).  Phosphorylated ATR and ATM phosphorylate the histone H2AX, 
which serves as a scaffold to recruit signaling molecules to the site of DNA damage and 
amplify the repair response.  The signaling cascades initiated by ATR and ATM lead to 
phosphorylation of the checkpoint kinases, Chk1 and Chk2, respectively, which inhibit 
cell cycle progession and promote DNA repair.  Recent studies have demonstrated a link 
between activation of the DNA damage response and upregulation of NKG2D ligands39.  
Therefore, we asked whether the DNA damage response pathway was activated in HIV-
infected cells and whether this pathway could be linked to A3G expression and/or 
upregulation NKG2D ligands in HIV-infected cells.  Indeed we observed that HIV 
infection increased phosphorylated Chk2 several fold and we noted further increases in 
Vif-deficient virus or Vif Y44A containing HIV (Figure 2.12a and b, NL–PIvif – p = 0.045 
when compared to NL–PI).  HIV infection and Vif expression also influenced Chk1 
phosphorylation in some donors, although to a lesser degree than Chk2 (Figure 2.12a and 
c).  Chk1 and Chk2 phosphorylation were affected by HIV (Figure 2.12a, b, and c) in a 
manner that mirrored the induction of NKG2D ligands in that it was Vpr-dependent and 
attenuated by Vif expression (compare Figure 2.12a to Figure 2.11d). 
 We also demonstrated that the magnitude of Chk2 phosphorylation correlated 
with A3G expression in both Vif-deficient HIV infected cells and mock infected controls 
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but was substantially higher in HIV-infected cells (Figure 2.12d, mock R2 = 0.75, NL-
PIvif– R2 = 0.92, lines significantly different p = 0.01).  In contrast, when A3G expression 
levels were compared to Chk1 phosphorylation there was no significant correlation and 
NL-PIvif– infected cells were indistinguishable from mock infected (Figure 2.12e, R2 = 
0.02, compare white and gray symbols).   
Phosphorylated H2AX (γH2AX) is specifically associated with sites of DNA 
damage40.  Therefore we determined whether HIV-infected primary T cells specifically 
upregulated the DNA damage response by analyzing γH2AX expression by western blot.  
Indeed, primary T cells infected with full-length HIV expressed γH2AX while mock-
infected controls did not (Figure 2.13a, compare lanes 1 and 2).  γH2AX expression was 
also determined for T cells infected with Vif-, Vpr- and Nef-deficient HIVs.  There was 
little change in γH2AX expression in the absence of Vif or Nef compared to full-length 
HIV-infected cells (Figure 2.13a, compare lanes 2 through 5).  However, NL-PIvpr - 
infected cells expressed roughly 10-fold less γH2AX than NL-PI-infected (Figure 2.13a, 
compare lanes 2 and 4), suggesting that Vpr stimulates γH2AX.  γH2AX expression in 
Vpr-deficient HIV infected cells remained 5-fold higher than in mock-infected cells 
(Figure 2.13a, compare lanes 1 and 4), indicating that Vpr-independent DNA damage 
response activation occurred in HIV-infected primary T cells.   
To further determine whether A3G directly induced DNA damage in HIV-
infected cells, CEM-SS CD4+ T cells stably expressing A3G or a negative control cell 
line were infected with HIV and γH2AX was assayed by western blot.  As shown in 
Figure 2.13b, mock-infected CEM-SS cells expressing A3G expressed 4-fold higher 
γH2AX than control CEM-SS cells, indicating that A3G expression alone activated the 
DNA damage response.  In CEM-SS cells, HIV infection upregulated γH2AX expression 
roughly 11-fold compared to mock-infected controls (Figure 2.13b and c).  However, 
HIV-induced γH2AX was roughly 3-fold higher in A3G expressing CEM-SS cells 
compared to negative control cells (Figure 2.13b and c).  In some experiments, γH2AX 
expression was higher in Vpr-expressing HIV infected CEM-SS cells than in Vpr-
deficient infected cells, although this was less consistent than in primary T cells.  
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Together these data indicated that A3G expression activated the DNA damage response 
and that it was amplified in HIV-infected cells. 
Discussion 
The APOBEC/AID family of cytidine deaminases are host factors that defend 
against pathogens.  In B cells, AID is necessary for antibody class–switch recombination 
and somatic hypermutation.  The “DNA damage” response that results leads to 
upregulation of NK cell activating ligands that transiently mark these cells as potentially 
dangerous6.  APOBEC3 proteins offer a strong intrinsic antiviral defense, however 
whether these deaminases also alert the cellular immune system to viral attack by 
upregulation of NK cell activating ligands was unknown.   
Recently it has been shown that there may be some overlap between adaptive and 
innate immune functions of the APOBEC3/AID family members.  AID has been shown 
to be protective against a number of viral pathogens, including Abelson murine leukemia 
virus, hepatitis B virus, and Epstein–Barr virus5, although the mechanism is unclear7.   
Whereas, mouse APOBEC3 is needed to efficiently generate neutralizing antibodies 
against Friend virus41.  In these studies, it was proposed that mouse APOBEC3 might 
play a role similar to that of AID in shaping the antibody repertoire.  Additionally, A3G 
has been shown to stimulate CTL recognition through the generation of defective 
translation products42.  Here, we provide evidence for a new function for A3G.  In 
addition to its protective effects on viral replication, we found that like AID6, A3G 
sensitized cells to NK cell recognition by the upregulation of NKG2D ligand expression. 
The effect of A3G on NKG2D ligand expression was partially counteracted by the HIV 
Vif protein in a manner that depended on the A3G-interaction domain of Vif.  It is 
intriguing to speculate that these effects on NKG2D ligands may also contribute to the 
A3G-dependent increase in CTL recognition42, as NKG2D serves as a co-stimulatory 
molecule in CTLs43, 44.  It will be interesting to determine whether there is a role of 
NKG2D in CTL recognition of HIV-infected cells.  
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Maximal upregulation of NK ligands also required HIV Vpr.  This effect of Vpr 
did not appear to be secondary to increased A3G expression levels because induction of 
A3G expression was independent of Vpr expression.   Upregulation of A3G expression 
by HIV containing cell supernatant has not previously been reported and the mechanism 
is unknown.  It is interesting to speculate that HIV-1 ssRNA, which is recognized by 
TLR7/8 45, induces the expression of A3G.  A3G expression is upregulated by Influenza 
virus ssRNA46, although it is unclear whether the upregulation of A3G involves PRR 
detection of virus.  Further study is required to explore this and other potential 
mechanisms. 
In addition, we found that both Vpr and A3G were required for maximal 
activation of the DNA damage response in HIV infected T cells.  The effect of A3G was 
direct because it was inhibited by wild type Vif but not by Vif mutants defective at 
binding and degrading A3G.  Furthermore, A3G expression in cell lines directly 
stimulated expression of the DNA damage marker γH2AX.  One model that explains the 
synergistic effects of Vpr and A3G is that Vpr expression stabilizes A3G-generated 
mutations through its previously reported effects on DNA repair enzymes UNG2, 
SMUG1 and HHR23A47, 48 (Figure 2.14).  Further study will be needed to investigate 
these and other possibilities.  
Interestingly, it has been shown that genetic variation at the A3G locus may 
predict disease progression in HIV infected people49.  It will now be of interest to 
determine whether these genetic alterations influence the effectiveness of the NK 
response. Furthermore, the development of small-molecule inhibitors of the Vif-A3G 
interaction may help augment NK cell activity 50-52. 
In conclusion, a number of host and viral factors likely affect the efficiency of NK 
cell killing and the role of NK cells in controlling HIV infection53.  Studies of KIR and 
HLA allelic frequencies among cohorts of HIV seropositive individuals have provided 
strong evidence for a role of NK cells in limiting HIV infection.  For instance, HIV-
infected individuals that encode both the NK cell activating KIR3DS1 allele and HLA-
Bw4-80Ile progress to AIDS at a slower rate than individuals encoding one or neither of 
the alleles54, which was later attributed to increased KIR3DS1 expression among HLA-
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Bw4+ donors55.  Also, a study of female sex workers revealed that there was a higher 
incidence of KIR gene heterozygotes that lacked the cognate inhibitory HLA ligand 
among HIV-exposed seronegative individuals than seropositive, which may be due to a 
lower threshold of NK cell activation with reduced inhibitory signals56.  These studies 
suggest that NK cell activity influences HIV infection and disease progression. The data 
presented here demonstrate that A3G expression enhances recognition of HIV-infected 
cells by natural killer cells through the activating receptor NKG2D.  Thus, therapeutic 
strategies aimed at augmenting the anti-viral activity of A3G may have the added benefit 
of promoting immune clearance of virally infected cells. 
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Methods 
Cell lines and culture conditions.  
K562 cells were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA) and were cultured according to their specifications.  Peripheral blood 
mononuclear cells (PBMCs) were isolated from buffy coats from HIV seronegative 
donors (American Red Cross, Lansing, MI and New York Blood Center, New York, NY) 
by Ficoll gradient centrifugation.  For NK cell isolation, whole PBMCs were cultured in 
R10 media and depleted of adherent cells for 90 minutes followed by immunomagnetic 
CD56+ selection (EasySep, StemCell Technologies).  NK cell cultures were at least 98% 
CD56+ as determined by flow cytometry (data not shown).  CD56+ NK cells were 
cultured in RPMI 1640 supplemented with 10% human type AB serum (Fisher scientific) 
plus penicillin, streptomycin, L-glutamine and 500 IU/ml rhIL-257.  For viral infections, 
non-adherent PBMCs were depleted of CD56+ and CD8+ cells by magnetic sorting 
(CD56+ EasySep, StemCell Technologies and CD8+ Dynabeads, Invitrogen).  Non–
adherent, CD56– CD8– PBMCs were stimulated with phytohemagglutinin lectin (PHA 
50µg/ml) and rhIL-2 (50 IU/ml) in R10 media for 48 hours prior to HIV-1 infection as 
previously described58.  CD56 and CD8 depleted PBMCs were greater than 95% CD56– 
and 99% CD8– as determined by flow cytometry (data not shown).  CEM-SS cells stably 
expressing A3G and negative control cells were cultured as described previously59. 
Lentivirus construction.   
The PLAP reporter HIVs, HXBePLAP, NL-PI and nef–, vpr–, vpu–, vpr–nef– 
accessory protein mutants have been reported previously25, 60.  NL-PIvif– and NL-PIvif–
vpr– were generated by inserting a frame shift mutation in vif at M29 of NL-PI and NL-
PIvpr–, respectively. Briefly, the SpeI to SalI fragments of NL-PI and NL-PIvpr– were 
subcloned into pLitmus38 (New England Biolabs), the NdeI site at position 83 of vif was 
filled-in by Klenow polymerization, and the SpeI to SalI fragments were re-ligated into 
NL-PI and NL-PIvpr–.  This mutation generated a premature stop codon and blocked viral 
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infection of non-permissive CCRF-CEM cells but had no effect on the infectivity of 
permissive CEM–SS cells (data not shown).  NL-PIvif–nef– was generated by inserting a 
frameshift mutation in NL-PIvif– by Klenow fill-in of the XhoI site at position 101 of nef.  
This Nef mutation eliminated MHC-I downmodulation as previously described25.    
The Y44A amino acid substitution of NL-PI Vif was generated by site directed 
mutagenesis.  In brief, the SpeI-SalI fragment of NL-PI was cloned into pLitmus38.  A 
point mutation was then introduced to generate an amino acid substitution at Tyr44 to Ala 
by PCR using Phusion HF polymerase (New England Biolabs) and the corresponding 
primers (Table 2.1, underlined sequence indicates mutation), producing a 701bp fragment 
from the NdeI site within vif to the SalI site within vpr.  The mutated product was then 
cloned into the NdeI to SalI sites of pLitmus38 NL-PI and sequenced through the entire 
amplified region.  The correct Y44A clone was then reintroduced into NL-PI using SpeI 
and SalI restriction sites. 
FG12 shβ2M, a short hairpin RNA (shRNA) expression construct targeting beta 2-
microglobulin (β2M) was cloned into the lentiviral vector FG1261 as described 
previously62.  Complimentary primers were annealed together and ligated into BglII and 
HindIII digested pRNAi63.  The primer sequences used are indicated in Table S1 where 
the target sequence is underlined.  The non-targeting FG12 shNC was used as a negative 
control62.  To confirm knockdown of β2M, CEM-SS cells stably expressing HA tagged 
MHC-I HLA-A*0201, HLA-B*5701, HLA-C*0401 and HLA-E allotypes58, 64 were 
transduced with FG12 shβ2M and assayed for HA surface expression at 5 days post 
transduction by flow cytometry (Figure 2.7).   
pNL-GIulbp1+ was constructed by two-step PCR amplification of IRESulbp1 (see 
below) and ligation into NheI and BglII sites within the env open reading frame of pNL-
G (pNL4-3-deltaE-EGFP)65.   
Ulbp1 DNA was isolated from a human cDNA library (MegaMan Human 
Transcriptome Library, Stratagene) by nested PCR amplification and cloned into XbaI 
and XhoI sites of pLitmus29 (New England Biolabs) using ulbp1 UTR forward 5’-
TGTCCACGGAGCTCCAGGTCTA-3’ and reverse 5’-AATGAGTGGCCTGA-
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GATGTTGAGC-3’ primers followed by a second round PCR with ulbp1 nested forward 
5’-AGCTCTAGAGCCACCATGGCAGCGGCCGCCAGCCCCGC-3’ and nested 
reverse 5’-CCGCTCGAGTCATCTGCCAGCTAGAATGAAGCAGA-3’ primers. The 
IRESulbp1 cassette was then amplified by PCR using pLitmus29ulbp1 and NL-PI as 
templates for ulbp1 and IRES, respectively, and the primers indicated in Table 2.1. The 
final construct was confirmed by sequence analysis and by direct detection of ULBP1 
protein using antibody staining and flow cytometric analysis of infected cells.  To 
generate pNL-GIulbp1+ nef – and pNL-Gnef – constructs, a frameshift mutation was 
inserted by Klenow fill-in of the XhoI site within nef.  The absence of Nef was confirmed 
by the inability of the construct to downmodulate MHC-I alleles HLA-A and HLA-B as 
determined by flow cytometric analysis. 
Virus production and T cell transduction.   
HIV-1 molecular clones were produced in 293T cells by transfection using 
Lipofectamine 2000 (Invitrogen) or linear polyetheleneimine, MT 25,000 (Polysciences, 
Inc.) as previously described66.  VSV-G pseudotyped shRNA expressing lentiviruses 
were produced in 293T cells as previously described62.  PHA stimulated primary T 
lymphocytes and CEM-SS cells were infected with virus in the presence of 8 µg/ml 
Polybrene as previously described25.  In some experiments, the infected PHA-stimulated 
primary T lymphocytes were cultured in conditioned media isolated from mock-infected, 
non-adherent, CD8-depleted PBMCs.  Conditioned media was added either 16 hours 
prior to spin infection or immediately after two hour spin infection and incubated for the 
duration of the experiment. 
Flow cytometric analysis.   
With the exception of NKG2D ligand staining, cells were stained in FACS buffer 
(PBS supplemented with 2% FBS, 1% human type AB serum plus 1% HEPES and 1% 
NaN3) and fixed in 2% paraformaldehyde as previously described58.  Antibodies to the 
following proteins were used for flow cytometry; PLAP (Sigma Aldrich and Serotec), 
ULBP1 (R&D Systems), CD3 (BD Pharmingen), CD56-PE-Cy5, CD16-PE-Cy5, CD8-
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Cy-Chrome (BD Pharmingen), CD4 (Serotec), CD4 (clone OKT4 67), CD4-AlexaFluor 
488 (Caltag), MHC-I (clone W632), HLA-A2 (clone BB7.2 68), HA (Covance), HLA-
Bw4, A9, A32 and HLA-Bw6, B77 anti-MHC–I (One Lambda). Isotype specific mouse 
immunoglobulin was used as negative control (BD Pharmingen).  Following 
unconjugated primary antibody staining, cells were incubated with fluorescently 
conjugated isotype specific secondary antibodies (Invitrogen or Caltag). 
For NKG2D ligand staining human serum was omitted from all buffers.  Cells 
were incubated with soluble rhNKG2Dfc (R&D Systems) and anti-CD3 antibody diluted 
in FACS buffer for 20 min at 4°C, washed once in cold FACS buffer, incubated with 
fluorescently conjugated goat anti-human Fc F(ab’)2 fragments (Jackson 
Immunoresearch) and isotype specific goat anti-mouse secondary antibody diluted in 
FACS buffer for 20 min at 4°C then washed once in cold FACS buffer.  Cells were then 
fixed in 2% paraformaldehyde and permeabilized with 0.1% TritonX-100 followed by 
incubation with fluorescently conjugated anti-Gag antibody (clone KC57, Beckman 
Coulter).  NKG2D ligand expression was determined for CD3 positive PBMCs.  All data 
was collected using FACScan or FACSCanto (BD Biosciences) instruments followed by 
analysis with FlowJo software (Tree Star, Inc.).   
NK cell cytotoxicity assay.   
NK cell cytotoxicity was determined by flow cytometry in a manner that was 
similar to a previously described method25, 31.  Briefly, K562 cells, HIV-1 infected and 
mock treated primary T lymphocytes were labeled with 500 µM CFSE (Invitrogen) one-
day prior to the NK cell assay and allowed to recover overnight at 37°C.  For shRNA and 
NL-G experiments, the target cells were not CFSE-labeled due to GFP expression by 
these viruses.  CFSE-labeled target cells were then co-incubated with purified, 
autologous CD56+ NK cells at increasing effector:target ratios for 4 hours at 37°C.  Cells 
were then washed in FACS buffer and stained for surface MHC-I, PLAP, CD56, CD16 
and 7-amino actinomycin D (7-AAD, Calbiochem) and analyzed by flow cytometry.  
Live target cells were determined by light scatter parameters, 7-AAD exclusion, CD56–
/CD16–/CFSE+ staining.  A constant number of fluorescent counting beads (Countbright 
 48 
beads, Invitrogen) were added to each tube and counted during cytometric acquisition.  
The normalized number of live cells was calculated as the number of cells counted times 
the fraction of beads counted. The percent target cell survival was determined as the 
percent normalized target cells remaining after NK cell incubation.  For some 
experiments, NK cells were incubated with 30 µg/ml anti-NKG2D (clone MAB149810, 
R&D Systems) or an IgG1 isotype control antibody for 30 minutes at room temperature 
and used in a 4 hr cytotoxicity assay, as previously described36.  
Western Blot Analysis.  
48 hours post HIV infection, PBMCs or CEM-SS cells were washed in PBS, 
lysed in RIPA buffer, and sonicated as previously described69.  Whole cell lysates were 
then normalized for total protein concentration, run on SDS–PAGE and analyzed by 
western blot using the following: phospho-Histone H2AX (S139), phospho-Chk1 (S345) 
and phospho-Chk2 (T68) polyclonal antibodies (Cell Signaling Technology), α-tubulin 
monoclonal antibody (Sigma), APOBEC3G antiserum70, anti-Vif (#319) monoclonal 
antibody71 and HIV-1SF2 p24 antiserum.  Membranes were then incubated with rat anti-
mouse IgG1-HRP or goat anti-rabbit IgG-HRP secondary antibodies (Invitrogen) and 
developed with the ECL Plus Western Blotting Detection kit (Amersham).  Background 
subtracted median band intensities were determined using Adobe Photoshop software and 
were normalized to tubulin levels for quantification. 
Statistical Analysis 
Statistically significant differences were determined by paired t test.  Linear and 
non-linear regressions were determined and compared using GraphPad Prism software. 
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Figure 2.1: K562 target cell recognition via a flow cytometric NK cell cytotoxicity 
assay  
CFSE labeled K562 target cells were co-incubated with IL-2 stimulated primary NK cells 
at increasing effector to target cell ratios in a 4 hr cytotoxicity assay.  After co-
incubation, cells were stained with 7-AAD, anti-CD56 and anti-CD16 (both PE-Cy5 
conjugated antibodies) and assayed for FL3 and CFSE expression.  Live CFSE+, CD56-
CD16-7-AAD-negative target cells were normalized to a constant number of inert 




Figure 2.2: HIV–infected T cells are resistant to NK cell recognition unless an 
NKG2D ligand is overexpressed 
(a) The NL4–3–deltaE–EGFP (NL–G) has been described previously65.  NL–GIulbp1+ 
was created by inserting an IRESulbp1 cassette within NL–G env.  In some experiments, 
nef - viruses were used, which contained a frame shift mutation in nef (indicated by the 
arrow).  (b) PHA activated primary T cells were infected with the indicated virus and co–
incubated with IL–2 stimulated autologous NK cells at a 2:1 effector to target ratio in a 4 
hour cytotoxicity assay.  Plots show MHC–I and GFP expression of 7–AAD– CD56– 
CD16–, live target cells.  The total number of GFP+ cells normalized to counting beads is 
indicated.  (c) Percent cell survival at increasing E:T ratios of HIV–infected cells, K562 
and mock infected controls from part b.  Data are representative of three independent 
donors.  (d) PHA activated primary T cells were transduced with NL–GIulbp1+, +/– nef 
or NL–G +/– nef control viruses.  ULBP1 expression of the GFP positive cells transduced 
with NL–G control virus (solid black line), NL–GIulbp1+ virus (dashed black line), and 
isotype control stained cells (solid gray histogram) were determined by flow cytometry.  
The fold change in ULBP1 expression relative to control virus is indicated. Data are 








Figure 2.3: NKG2D ligand overexpression induces NK cell lysis in cells independent 
of reduced MHC-I. 
(a) PHA activated primary T cells were infected with the indicated viruses and co-
incubated with autologous NK cells as in Figure 2.2b.  Plots show MHC–I and GFP 
expression of 7–AAD– CD56– CD16–, live target cells.  The total number of GFP+ cells 
normalized to counting beads is indicated.  (b) Percent cell survival at increasing E:T 
ratios of HIV–infected cells, K562 and mock infected controls from part a.  Data are 
















Figure 2.4: NKG2D ligands upregulation by HIV depends on Vpr and is attenuated by Vif. 
(a) The NL–PI virus expresses PLAP to mark infected cells; accessory protein mutants were made of these constructs and are 
indicated by the black arrows25, 60.  (b) Total NKG2D ligand expression of primary T cells infected with NL–PI (solid black line), NL–
PI accessory protein mutants (dashed black line) and mock treated control (shaded gray histogram).  Cells were analyzed for 
rhNKG2Dfc staining and mean fluorescence values are shown for all conditions.  For all samples, only alive, CD3+ cells were gated.  
(c) Fold difference in NKG2D ligand expression relative to mock treated controls for independent donors, each represented by a 
different character.  Black bars represent the mean change in ligand expression for each virus.  Statistical analyses were calculated by 














Figure 2.5: Vif and Nef limit NKG2D ligands upregulation by Vpr. 
(a) NKG2D ligand expression of primary T cells infected with NL–PIvpr– (solid black line) or the indicated NL–PI accessory protein 
mutant (dashed black line) and mock treated controls (shaded gray histogram).  Cells were stained with rhNKG2Dfc and mean 
fluorescence values are shown for all conditions.  (b) Fold difference in NKG2D ligand expression relative to mock treated controls 
for independent donors, each represented by a different character.  Black bars represent the mean change in ligand expression for each 



















Figure 2.6: Vif limits NK cell recognition of HIV-infected T cells. 
Activated, primary T cells were infected with NL–PI +/– vif, labeled with CFSE, and co–
incubated with IL–2 stimulated autologous NK cells at a 5:1 and 2:1 effector to target cell 
ratios in a 4 hr cytotoxicity assay. The percentage of cells surviving NK cell co–













Figure 2.7: β2M knockdown reduces MHC-I surface expression. 
CEM-SS cells stably expressing HA-tagged MHC-I alleles HLA-A2, HLA-B5701, HLA-
Cw4 or HLA-E 64, 72 were transduced with FG12 shNC (solid gray line), FG12 shβ2M 
(solid black line) or FG12 shβ2M plus HxBePLAP (dashed black line) and stained for HA 




Figure 2.8: Nef limits NK cell recognition of HIV-infected T cells. 
Activated, primary T cells infected with NL–PI or NL–PInef– plus a lentivirus encoding  
(a) negative control or (b) β2M–targeting shRNAs were co–incubated with IL–2–
stimulated, autologous NK cells at a 5:1 effector to target ratio in a 4–hour cytotoxicity 
assay.  Flow cytometry plots showing PLAP and MHC–I expression of shRNA 
transduced (GFP+), CD56– CD16– 7–AAD–, live target cells are presented with and 
without NK cells.  The numbers of target cells within the high (upper quadrants) and 
moderately reduced (bold gray boxes) MHC–I gates normalized to counting beads are 
indicated.  (c) The percentage of cells surviving NK cell treatment at increasing E:T 
ratios for NL–PI and NL–PInef– infected T cells and K562 cells.  Values were normalized 
to the percentage of mock–infected T cells surviving when transduced with the shNC 
lentivirus alone.  Experiments were repeated with two independent donors and 





Figure 2.9: Vpr-dependent NKG2D ligand expression induces NK cell recognition of HIV-infected T cells. 
(a) Activated, primary T cells were infected with NL–PIvif –vpr+nef – or NL–PIvif+vpr –nef – plus a lentivirus expressing β2M–
targeting or control shRNA and were then co–incubated with autologous NK cells in a 4–hour cytotoxicity assay.  PLAP and MHC–I 
expression of, CD56– CD16– 7–AAD–, live target cells incubated with and without NK cells is shown.  The values indicate the number 
of cells normalized to counting beads within each quadrant.  (b) The percentage of cells surviving NK cell treatment at increasing E:T 
ratios.  For this analysis, data was compiled only from the shβ2M–expresing cells with low MHC–I or high MHC–I for shNC treated 
cells.  Data are representative of two independent donors.  (c) Activated, primary T cells were infected as in part D and then co–
incubated with autologous NK cells, which had been pre–incubated with isotype control, anti–NKG2D or no antibodies.  The NK cells 
were added at a 1:1 ratio with the autologous primary T cells. The percentage of cells surviving a 4–hour co–incubation was 
calculated.  Uninfected, CFSE–labeled K562 cells were included as control and the percentage of CFSE+, CD56– CD16– 7–AAD–, live 















Figure 2.10: Induction of A3G with conditioned supernatant upregulates NKG2D ligands. 
(a) Experimental time line.  PHA activated CD56– CD8– cells were treated with conditioned supernatant from CD8– PBMCs at the 
times indicated, infected with HIV, and assayed by flow cytometry and western blot at 48 hours post infection.  (b) NKG2D ligand 
and Gag expression of mock or NL–PIvif– infected CD3+ cells treated with conditioned supernatant or control media.  The mean 
fluorescence intensity is indicated for the total Gag– and Gag+ populations.  (c) Western blot analysis of whole cell lysates from three 
independent donors treated with conditioned supernatant (-16hr or 2hr) or media alone (-).  Band intensities were quantified (Adobe 
Photoshop) and relative A3G expression was determined after normalizing for α-tubulin expression.  (d) Plot of relative A3G 
expression from part c versus NKG2D ligand normalized to control media treated cells.  Each symbol represents data from an 






Figure 2.11: Induction of A3G with HIV infection upregulates NKG2D ligands. 
(a) Western blot analysis of whole cell lysates from PHA activated primary T cells 
infected with NL-PI or accessory protein mutants.  Band intensities were quantified 
(Adobe Photoshop) and relative A3G expression was determined after normalizing for α-
tubulin.  (b) Plot of A3G expression of NL-PI or accessory protein mutant infected cells 
normalized to mock infected for several independent donors (indicated by different 
symbols).  Mean fold change in A3G expression is indicated by the black bars.  (c) Plot 
of A3G expression versus NKG2D ligand expression of mock infected (white symbols) 
or NL-PIvif- infected (gray symbols) cells for several independent donors (indicated by 
different symbols).  Data are normalized to mock infected, control media treated cells for 
each donor and linear correlation is indicated. Mock R2 = 0.66, NL-PIvif- R2 = 0.84.  (d) 
NKG2D ligand expression of NL-PI or accessory protein mutant infected T cells from 
several independent donors (indicated by different symbols, all donors are different from 
those shown in Figure 2) normalized to mock infected controls.  Mean change in ligand 
expression is indicated for each virus by the black bars.  Statistical analyses were 
performed by paired t test comparing accessory protein mutant to wild type (NL-PI) 










Figure 2.12: Activation of the DNA damage response in HIV infected primary T 
cells depends on A3G expression and is attenuated by Vif. 
(a) Representative western blot analysis of whole cell lysates from PHA activated 
primary T cells infected with the indicated virus.  (b-e) Summary of western blot 
analyses.  Data were derived from western blot analyses quantified using Adobe 
Photoshop software and normalized to α-tubulin expression.  (b) Chk2 phosphorylation 
at T68 and (c) Chk1 phosphorylation at S345 were measured for eight independent donors, 
each represented by a different symbol. Mean fold change relative to mock for each virus 
is represented by the black bars.  Statistical analyses were performed by paired t test 
comparing each mutant virus to full-length NL-PI infected. * indicates p ≤ 0.05.  (d and 
e) A3G expression versus (d) Chk2 phosphorylation at T68 or (e) Chk1 phosphorylation at 
S345 for five independent donors each represented by different symbols.  Mock infected 
samples plus conditioned supernatant are represented by open symbols.   Infected 
samples plus or minus conditioned supernatant are represented by gray symbols.   Data 
from each donor were normalized to results from autologous mock-infected cells treated 
with control media.  Separate mock and NL-PIvif– linear regressions are indicated for part 
d.  Mock R2 = 0.75, NL- PIvif–  R2 = 0.92, p = 0.011.  Linear regression of the 







Figure 2.12: Activation of the DNA damage response in HIV infected primary T 








Figure 2.13: Phosphorylation of the DNA damage marker H2AX is induced by A3G 
and HIV infection. 
(a) Representative western blot analysis of whole cell lysates from PHA stimulated 
primary T cells infected with the indicated viruses.  (b) Representative western blot 
analysis of whole cell lysates from CEM-SS cells expressing A3G or negative control 
cells infected with the indicated viruses.  Data are representative of three independent 
experiments (c) Summary of western blot analysis from part b.  Data were derived from 
western blot analyses quantified using Adobe Photoshop software and normalized to α-
tubulin expression.  Mean fold change in expression above mock-infected CEM-SS 














Figure 2.14: Proposed model for A3G-induced DNA damage response activation 
and NKG2D ligand expression. 









Table 2.1: Primers used in this study 
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Chapter 3  
Discussion and future directions 
Overview of Dissertation 
In this dissertation I have investigated HIV-1 evasion of NK cell recognition.  I 
initially characterized the NK cell activating ligand expression and lysis of primary T 
cells infected with a panel of HIV-1 accessory protein mutants.  These studies led to a 
more detailed analysis of the mechanism of Vif-mediated ligand inhibition and Vpr-
dependent ligand upregulation.  The following were the key findings of the work: 
• HIV-1 Vif and Nef reduce NK cell recognition of HIV-infected primary T cells 
by limiting NKG2D ligand upregulation. 
• HIV-1 Vpr induces NK cell lysis of HIV-infected primary T cells by upregulating 
NKG2D ligands. 
• Expression of the cytidine deaminase, APOBEC3G, is upregulated in HIV-
infected primary T cells. 
• APOBEC3G expression activates the cellular DNA damage response indicated by 
phosphorylation of the histone H2AX. 
• APOBEC3G expression correlates with Chk2 phosphorylation and NKG2D 
ligand expression in HIV-1 Vpr-expressing primary T cells. 
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I. NKG2D ligand expression in HIV-infected T cells 
Discussion 
NK cell recognition of a target cell depends on a balance of inhibitory and 
activating signals1.  NK cell inhibitory receptors detect MHC-I molecules expressed on 
the surface of target cells1.  However, sufficient activating ligand expression on target 
cells will induce NK cell lysis even in the presence of inhibitory signals2.  Thus viruses 
commonly reduce the expression of NK cell activating ligands to evade recognition by 
NK cells3-9.  This dissertation analyzes the relative contributions of inhibitory and 
activating signals in the NK cell recognition of HIV-infected cells. 
In HIV infection, residual expression of the MHC-I allotypes HLA-C and -E send 
inhibitory signals to KIRs and CD94-NKG2A molecules on the surface of NK cells10.  
Although this contributes to insufficient NK cell recognition, I show that NK cell 
activating signals are also limiting in HIV infection (Figure 2.2).  In HIV-infected 
primary T cells the Vpr protein upregulates the expression of ligands recognized by the 
NKG2D activating receptor (Figure 2.4)11, 12.  However, the expression of NKG2D 
ligands is limited by the HIV-1 Vif and Nef proteins (Figure 2.4).  I also show that the 
modulation of NKG2D ligands affects NK cell recognition of HIV-infected primary T 
cells (Figures 2.6, 2.8, 2.9).  Therefore, the combination of residual MHC-I and limited 
NKG2D ligand expression results in insufficient NK cell recognition of HIV-infected 
primary T cells. 
The cellular factors involved in NKG2D ligand upregulation by HIV-1 were also 
analyzed.  NKG2D ligands are upregulated when cells experience genotoxic stress13.  
This signals to NK cells the presence of a potentially tumorigenic cell.  Therefore, if the 
damaged cell is unable to repair the DNA damage, circulating NK cells will respond and 
lyse the damaged cell.  One form of damage cells commonly encounter is the presence of 
uracil in their DNA, which occurs either via dUTP misincorporation or cytidine 
deamination14.  The AID cytidine deaminase is normally expressed by activated lymph 
node germinal center B cells and mediates antibody somatic hypermutation (SHM) and 
class switch recombination (CSR)15, 16.  However, retroviral infection ectopically 
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upregulates AID expression17 via a poorly defined mechanism involving the transcription 
factor NF-κB18.  The DNA damage as a result of AID expression upregulates NKG2D 
ligand expression17. Since APOBEC3 proteins and AID are members of the same family 
of cytidine deaminases19, 20, the data presented in this dissertation showing that 
APOBEC3G (A3G) also upregulates NKG2D ligand expression are consistent. 
A3G inhibits HIV infection via mechanisms both dependent and independent of 
its enzymatic activity21 but it is unclear whether the products of these mechanisms 
provide the DNA damage signal that leads to NKG2D ligand upregulation.  The HIV-1 
genome is hypermutated by A3G during cDNA synthesis22-24.  The integration of this 
hypermutated stretch of cDNA would likely trigger a DNA damage response due to the 
integration event, which has been shown to activate the ataxia–telangiectasia mutated and 
RAD3-related (ATR) kinase 25, or due to hyperuracilation of the genome.  When uracil 
incorporation is high, DNA fragmentation can occur due to the removal of the uracil 
residues in close proximity to one another26.  Normally stretches of ssDNA induces an 
ATR response, leading to Chk1 phosphorylation27.  However, in our system there is no 
correlation between Chk1 phosphorylation and A3G expression (Figure 2.12e).  These 
data may suggest free dsDNA ends result from A3G expression, which would initiate an 
ATM response28.  Alternatively, A3G inhibits the completion of viral cDNA synthesis, 
which results in the accumulation of an abnormal DNA intermediate that fails to 
integrate29.  The presence of this abnormal DNA would likely activate a DNA damage 
response because of the free DNA ends, although it is hard to predict whether it would 
activate ATM or ATR.  HIV cDNA synthesis is inhibited by A3G prior to the second 
strand transfer event, resulting in a DNA with both single stranded and double stranded 
regions29.  Therefore, both ATM and ATR responses could be activated if this abnormal 
DNA were the signal. 
In the absence of HIV infection, A3G modestly activated the DNA damage 
response, indicated by γH2AX and low-level NKG2D ligand expression (Figure 2.11c 
and 2.13).  Since A3G resides in the cytoplasm, it is unclear how it is activating the 
damage response in uninfected cells.  One possibility is A3G gains access to the cellular 
DNA during replication following nuclear envelope breakdown, at which point, stretches 
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of ssDNA may be accessible for deamination.  However, UDG enzymes would likely 
repair some of the deaminated nucleotides, which may explain the intermediate damage 
response phenotype.  Other A3 isoforms might also activate the DNA damage response 
and may have greater access to cellular DNA due to their nuclear localization30.  Further 
characterization of the cellular response to A3 expression may reveal a global 
upregulation of the DNA damage response. 
Downstream Chk2 phosphorylation and significant NKG2D ligand upregulation 
required HIV infection and Vpr expression (Figure 2.11 and 2.12).  It is well established 
that A3G packaged in the viral particle deaminates the viral genome during cDNA 
synthesis22-24.  However, in our experiments virus was produced in cells lacking A3G; 
therefore, viral particles would not contain A3G.  Deamination of the viral genome would 
consequently have to result from A3G within the target cell.  Since A3G is cytoplasmic, 
it seems likely that deamination of the HIV genome would occur if A3G localized to the 
site of active reverse transcription, although further experimentation is required to 
confirm this. 
HIV-1 Vpr has consistently been shown to upregulate NKG2D ligands by our 
group and others11, 12, although it is unclear whether this response is intentional.  Vpr’s 
role in HIV infection is ill defined, yet it seems likely that NKG2D ligand upregulation is 
a consequence of Vpr expression rather than the objective.  Vpr activates ATM and ATR 
responses and causes arrest of the cell cycle at the G2/M transition31-34.  Vpr targets 
cellular proteins for proteasomal degradation by linking them to an E3 ubiquitin ligase 
complex35-37, which is necessary for cell cycle inhibition38.  The UNG2 and SMUG1 
uracil DNA glycosylase (UDG) enzymes and HHR23A protein are known targets of 
Vpr39-43.  Interestingly, these are all involved in the removal of mutated nucleotides from 
DNA14, 44.  Furthermore, virion associated UNG2 has been shown to degrade A3G-
deaminated HIV cDNA45.  Therefore, one model is that the degradation of these repair 
proteins by Vpr would result in stabilization of the DNA damage signal and upregulation 
of NKG2D ligands (Figure 2.14).  In this case, the cell may recognize incorporated uracil 
residues as the damage signal, although further investigation is required to confirm this.  
Preliminary evidence presented in Appendix 1 suggests the degradation of UNG2 or 
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HHR23A by Vpr induces NKG2D ligand expression (Figure A1.1).  However, mutating 
the UNG2 and HHR23A binding sites of Vpr did not completely inhibit NKG2D ligand 
expression, implying that other cellular targets are involved.  Alternatively, multiple 
DNA damage signals may be generated during HIV-1 infection that have varying degrees 
of susceptibility to UDG repair.  Further investigation is required to clarify the 
mechanism of Vpr-mediated NKG2D ligand expression.   
Cells detect pathogen associated molecular patterns via pattern recognition 
receptors (PRRs), such as TLRs, RLHs, and NLRs46-50.  PRR activation leads to the 
production of proinflammatory cytokine and type I IFN production.  In the case of virus 
infections, viral nucleic acids typically serve as ligands for PRRs49.  This is true for HIV-
1 infection, as a GU rich region of ssRNA within U5 of the HIV-1 LTR is recognized by 
TLR8 51.  Although these studies were performed in dendritic cells, CD4+ T cells also 
express TLR8 in endocytic compartments52.  Therefore, HIV-1 RNA could be recognized 
by these TLRs if trafficked to these endosomes.  In addition to cytokine production, TLR 
activation has also been shown to induce NKG2D ligand expression53-55.  Thus, the HIV-
1 RNA genome itself could be sufficient for NKG2D ligand expression, although 
maximal expression would be Vpr-dependent.   
The inhibition of NKG2D ligand expression by Vif can be explained in part by its 
effects on A3G expression levels.  However, we also found that A3G expression varied 
among donors (Figure 2.10c), which may suggest that A3G expression differences 
influence HIV susceptibility by affecting NK cell recognition of infected cells.  
Furthermore, apobec3g is polymorphic and functional differences in A3G among the 
human population may affect NK cell recognition of HIV-infected cells30.  
The mechanism by which Nef limits NKG2D ligand expression is unclear.  
However, Nef reduces Vpr-dependent NKG2D ligand upregulation (Figure 2.5).  Since 
Vpr expression induces NKG2D ligands by activating the DNA damage response (Figure 
2.12a and 2.13a)11, 12, it is likely that Nef affects DNA damage response activation.  Nef 
links cellular targets to adaptor proteins, redirecting the target proteins to lysosomal 
compartments for degradation56.  One potential model for Nef-mediated NKG2D ligand 
inhibition would be that Nef targets one or more proteins involved in DNA damage 
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response signaling for lysosomal degradation.  Data presented in Appendix 2 indicate that 
Nef limits the upregulation of NKG2D ligands rather than downmodulating pre-existing 
ligand surface expression, which would fit with this proposed model.  Together these data 
may suggest a novel mechanism of Nef-mediated protein downmodulation.  However, 
further investigation is required to characterize this mechanism. 
Future directions 
A greater understanding of the mechanism of NK cell inhibition by HIV-1 may 
lead to new treatment strategies by reversing inhibition of NK cell lysis.  Two aspects of 
the mechanism that require further clarification are identification of the DNA damage 
signal induced by A3G and the requirement for Vpr in NKG2D ligand upregulation.  As 
stated previously, the HIV-1 ssRNA genome, uracil incorporation, and/or cDNA 
intermediates may be recognized by the cell as “DNA damage”.  It would be informative 
to determine whether induction of the DNA damage response by A3G requires its 
enzymatic activity, which may help identify the damage signal.  Preliminary evidence 
presented in Appendix 1 suggests that the degradation of UNG2 and HHR23A by Vpr 
induces NKG2D ligand expression (Figure A1.1).  These data suggest uracil 
incorporation is the damage signal, although this must be confirmed.  However, UNG2 
and HHR23A binding mutants did not completely reverse ligand upregulation (Figure 
A1.1).  Since UDG enzymes have overlapping function57, complete reversal may only be 
observed if Vpr binding and degradation of all cellular targets is disrupted.  Alternatively, 
multiple A3G-induced damage signals may be present that are detected by various DNA 
repair mechanisms.  Thus, identification of the damage signal might lead to the detection 
of the enzymes involved in the repair, or visa versa. 
All of our studies to date have analyzed the role of the A3G enzyme in the 
activation of the DNA damage response, but there are a total of 7 known APOBEC3 (A3) 
isoforms that could also activate the DNA damage response.  Since NKG2D ligand 
expression is limited by Vif, it would be informative to determine whether other A3 
isoforms that are targeted by Vif activate the DNA damage response in HIV infected 
cells.  Although A3G is the strongest inhibitor of HIV-1 infection, A3B, A3C, A3D/E 
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and A3F are all degraded by Vif and inhibit HIV infection to varying degrees30.  Of these, 
A3B, A3C and A3D/E localize to the nucleus30, which may make them likely candidates 
for deaminating the genome. 
The studies presented in this dissertation were solely done in primary T cells, 
although macrophages, dendritic cells (DCs) and hematopoetic progenitor cells (HPCs) 
remain as targets of HIV-1 infection58-60.  Therefore, it would be informative to repeat 
these studies in other relevant cell types.  Interestingly, the amount of cytoplasmic dUTP 
varies from one cell type to another61.  If uraciliated DNA activates the DNA damage 
response, one might expect those cells with higher cytoplasmic dUTP to have increased 
damage response activation.  Also, DCs are thought to be one of the first sites of HIV-1 
infection and transmit HIV to CD4+ T cells58.  A greater understanding of how HIV-1 
evades immune recognition in DCs may lead to therapies aimed at preventing infection of 
these early targets. 
The ultimate goal of these studies is to translate this knowledge into new 
therapeutic strategies aimed at reducing HIV-1 infection.  A3G is a potent inhibitor of 
HIV-1 infection and, as shown in this dissertation, induces NK cell activating ligand 
expression.  Thus, blocking the interaction between Vif and A3G is an attractive target 
for drug development.   Small molecule inhibitors of the Vif-A3G interaction have been 
developed and they have been shown to decrease infectivity of the virus in vitro62, 63.  It 
would be interesting to determine if these inhibitors also rescue NKG2D ligand 
expression and NK cell recognition of HIV-infected cells.   
While CTLs specifically recognize target cells presenting antigen in the context of 
MHC-I molecules64, it was recently shown that NKG2D expressed on CTLs serves as a 
co-stimulatory molecule65.  It would be informative to determine whether NKG2D is 
involved in CTL recognition of HIV-infected cells.  HIV-1 Nef reduces both MHC-I and 
NKG2D ligand surface expression (Figure 2.4 and A2.1)7, 66.  However, Nef-mediated 
CTL inhibition has only been attributed to MHC-I downmodulation67.  Our system of 
reducing total MHC-I by β2M knockdown may provide a means to separate the effects of 
Nef on MHC-I and NKG2D ligand expression.  These findings may reveal a new strategy 
of CTL immune evasion employed by HIV-1.  A3G enhances CTL recognition of HIV-
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infected cells68, which may provide further evidence that NKG2D stimulation is 
involved, as we have shown that A3G also enhances NKG2D ligand expression.  Finally, 
domains within Nef have specialized roles in the downmodulation of MHC-I and CD4 
molecules56.  It would be interesting to determine whether NKG2D ligand 
downmodulation by Nef can be attributed to one of these domains.  
II. APOBEC3G upregulation in HIV-infected T cells 
Discussion 
A3G is an intrinsic inhibitor of virus infection and endogenous retroelement 
transposition69-74 that is expressed in the cytoplasm of many cell types, including CD4+ T 
cells, dendritic cells, monocytes, and hepatocytes20, 75-77.  As stated previously, 
proinflammatory cytokines and type I IFNs are produced in response to viral infection.  
Several of these cytokines, including IFN-α, IFN-γ, IL-2 and IL-15 have been shown to 
induce A3G expression76-78.   Additionally, type I IFN expressed in response to the TLR3 
ligand poly(I:C) has been shown to induce A3G expression79.  I show in this dissertation 
that HIV infection of primary T cells stimulates A3G protein expression, although the 
mechanism remains unclear.  The data suggest that A3G expression is induced within 
infected cells and not uninfected cells in the culture.  This can be explained by the finding 
that A3G upregulation is predominantly observed in the absence of Vif or in A3G-
binding mutants (Figure 2.11).  If cytokines produced in response to HIV infection were 
inducing A3G expression, one would expect to observe A3G upregulation throughout the 
culture.  Only a percentage of cells (upwards of 30%) are infected; therefore, the majority 
of cells would not express Vif and degrade A3G.  Thus, no difference in A3G 
upregulation would be expected if it were cytokine dependent.  These data suggest that 
the cells recognize the virus and the infected cells upregulate A3G protein expression.   
These observations are consistent with a recent study of A3G expression in HIV-
infected female sex workers80.  In this study, A3G mRNA expression was determined 
both pre- and post-infection within the cohort, where A3G mRNA was significantly 
higher post-HIV infection80.  Although the viral signal that induces A3G upregulation is 
 78 
yet to be determined, recognition of the viral RNA genome by PRRs is a possibility.  A 
recent study indicated that Influenza virus infected cell lines upregulated A3G mRNA 
expression by a mechanism dependent on viral RNA81.  Further investigation is required 
to determine whether the recognition of HIV-1 RNA also induces A3G expression.  
These data may indicate that the upregulation of A3G is an innate response to RNA virus 
infection. 
Future directions 
Several questions remain that must be addressed to understand the mechanism of 
HIV-induced A3G upregulation.  First, it would be informative to determine whether 
HIV-1 RNA upregulates A3G expression and to determine the cellular receptor that 
detects the RNA.  One likely candidate receptor is TLR8, which has been shown to 
recognize HIV-1 RNA51.  In other cell types, TLR3 activation induces A3G expression79.  
Since TLR3 and TLR8 signaling lead to the activation of common transcription factors49, 
it is possible that TLR8 recognition of HIV RNA also induced A3G expression.  Notably, 
the transcription factor NFκB is activated by TLR3 and 8 and is required for the 
retrovirus-dependent upregulation of AID18, 49.  Therefore, A3G upregulation may also be 
NFκB dependent.  The RLH receptors could also be involved in HIV-1 RNA detection, 
as they detect cytoplasmic viral ssRNA and activate NFκB, as well as other transcription 
factors47, 50.  Further investigation is needed to determine if PRRs are involved in HIV-
induced A3G upregulation.   
It is also enticing to speculate that A3 upregulation is a general response to virus 
infection.  In the case of HIV-1 infection it would be interesting to determine whether 
other A3 isoforms are also upregulated.  Alternatively, it would be interesting to 
determine whether other RNA viruses upregulate A3G expression.  The recent finding 
that Influenza virus RNA induces A3G expression may indicate that other RNA viruses 
would do the same81.  A3 deaminases are potent inhibitors of viral infection30; therefore, 
upregulating their expression in response to virus may greatly enhance resistance to 
infection. 
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HIV-1 has several mechanisms of evading recognition by adaptive and innate 
immune responses.  By counteracting these immune evasion strategies, HIV-infected 
cells may be rendered susceptible to immune recognition.  Thus, a greater understanding 
of the factors involved in the recognition of HIV-1, such as those presented in this 
dissertation, may prove vital for the treatment of infection. 
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Appendix 1  
HIV-1 Vpr-mediated NKG2D ligand upregulation involves UNG2 and HHR23A 
binding 
In this dissertation I investigated the susceptibility of HIV-1 infected primary T 
cells to NK cell recognition.  These studies revealed that ligands recognized by the 
NKG2D activating receptor are upregulated in HIV-infected cells.  Maximal NKG2D 
ligand upregulation correlated with APOBEC3G (A3G) levels and required HIV-1 Vpr 
expression.  One possible explanation for these synergistic effects is Vpr stabilizes 
mutations generated by A3G by inhibiting DNA repair (Figure 2.14).  Vpr has been 
shown to interact with several proteins involved in DNA repair including, the uracil DNA 
glycosylases, UNG2 and SMUG1, and the nucleotide excision repair protein HHR23A1-5.  
Mutating the tryptophan at position 54 (W54) of Vpr to arginine and mutating the 
histidine at position 45 (H45) of Vpr to glutamine disrupt UNG2 (ref1, 6) and HHR23A3 
binding, respectively.  The SMUG1 binding site of Vpr has not been characterized.  Thus, 
we determined whether disrupting the association between Vpr and UNG2 or HHR23A 
affected NKG2D ligand upregulation in HIV-infected primary T cells. 
To address this question, W54R and H45Q single amino acid substitutions were 
generated within vpr of the molecular clone NL-PInef - (Figure A1.1a).  These mutations 
were made in a Nef-deficient background to rule out inhibitory effects of Nef on NKG2D 
ligand expression.  Mutating these amino acids had no effect on protein expression 1, 3 
(data not shown).  As shown in Figure A1.1b and c, primary T cells infected with HIV 
expressing wild-type Vpr had an average of 5-fold higher NKG2D ligand expression than 
cells infected with a Vpr-deficient HIV (compare NL-PInef –vpr+and NL-PInef –vpr -, p < 
0.01).  Mutating the UNG2 binding site of Vpr reduced the NKG2D ligand expression by 
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1.6-fold among the six donors tested (Figure A1.1b and c, compare NL-PInef –vpr+ and 
NL-PInef - Vpr W54R, p < 0.05). Primary T cells infected with a Vpr mutant unable to 
bind HHR23A also expressed less NKG2D ligand than WT Vpr (Figure A1.1b and c, 
compare NL-PInef –vpr +and NL-PInef –Vpr H45Q).  Together these data suggest that 
Vpr upregulates NKG2D ligands via a mechanism involving UNG2 and HHR23A 
binding. 
NKG2D ligand upregulation was only partially reversed by inhibiting either 
UNG2 or HHR23A binding.  A Vpr double mutant that disrupted binding of both UNG2 
and HHR23A was also tested, although its expression was less than WT Vpr (data not 
shown).  Therefore, we cannot rule out an additive effect of binding both DNA repair 
proteins on NKG2D ligand upregulation.  Since UDG enzymes have overlapping 
functions7, it is possible that the inability to completely inhibit Vpr-mediated NKG2D 
ligand upregulation is due to compensatory effects of other UDGs.  Alternatively, 
multiple A3G-mediated DNA damage signals could be present, which may have different 
susceptibilities to UDG or HHR23A-dependent repair.  Further study is needed to 
characterize the mechanism of Vpr-dependent NKG2D ligand expression to rule out 
these and other possibilities. 
Methods 
Lentivirus construction 
The NL-PInef - and nef –vpr - molecular clones have been reported previously8, 9.  
The H45Q and W54R amino acid substitutions of NL-PInef - Vpr were generated by site 
directed mutagenesis.  In brief, the SpeI-SalI fragment of NL-PI was cloned into 
pLitmus38.  A point mutation was then introduced to generate an amino acid substitution 
at His45 to Gln and Trp54 to Arg by PCR using Phusion HF polymerase (New England 
Biolabs) and the following primers: NL4-3 Vif NdeI fwd 5’-
TTAACACATGGAAAAGATTAGTAAAACACC-3’, NL4-3 Vpr SalI rev  5’-
CCCGTCGACACCCAATTCTGAAA-3’, and the internal NL4-3 Vpr W54R 5’-
ACTTACGGGGATACTAGGGCAGGAGTGGA-3’ and NL4-3 Vpr H45Q 5’-
 87 
ACTTAGGACAACAGATCTATGAAACTTAC-3’ primers plus their reverse 
compliments (underlined bases indicate mutation sites).  The full amplicon is a 701bp 
fragment from the NdeI site within vif to the SalI site within vpr.  The mutated product 
was then cloned into the NdeI to SalI sites of pLitmus38 NL-PI and sequenced through 
the entire amplified region.  The correct H45Q and W54R clones were then reintroduced 
into NL-PInef - using SpeI and SalI restriction sites. 
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(a) The NL-PI virus expresses PLAP to mark infected cells; accessory protein mutants 
were made of this construct and are indicated by the black arrows.  Sites of amino acid 
substitution are indicated.  (b) NKG2D ligand expression of primary T cells infected with 
the indicated virus or mock-infected.  Mean fluorescence values within the Gag p24+ and 
Gag p24- populations are shown.  Only alive, CD3+ cells were gated.  (c) Fold difference 
in NKG2D ligand expression relative to mock treated controls for independent donors, 
each represented by a different character.  Black bars represent the mean change in ligand 
expression for each virus.  Statistical analyses were calculated by paired t test of 
accessory protein mutants compared to NL–PInef -vpr +. 
 
Figure A1.1: Vpr-dependent NKG2D ligand upregulation involves UNG2 
and HHR23A binding. 
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Appendix 2  
HIV-1 Nef-mediated NKG2D ligand inhibition 
Much of this dissertation focuses on the synergistic relationship between A3G and 
Vpr that leads to the upregulation of NKG2D ligands.  However, negative factor (Nef) is 
an integral part of HIV-1 immune evasion.  There are two main functions of Nef: CD4 
and MHC-I downmodulation.  However, we show that Nef also limits the expression of 
NKG2D ligands on the surface of primary T cells. 
CD4 is the major receptor for HIV-1 and limits viral particle budding and release 
when not removed from the cell surface1, 2.  In HIV-infected cells, the combined effects 
of the Nef, Vpu and Env proteins downmodulate CD4, although Nef is sufficient for CD4 
downmodulation.  While the mechanism is incompletely defined, Nef binds to the CD4 
cytoplasmic tail domain, removes it from the cell surface, and targets it for lysosomal 
degradation (reviewed in 3).  The mechanism of Nef-mediated MHC-I downmodulation is 
better characterized and serves to limit viral peptide presentation to CTLs4.  Nef has been 
shown to selectively bind the cytoplasmic tail domains of HLA-A and -B molecules early 
in the secretory pathway3, 5, 6.  This leads to the recruitment of the cellular adaptor 
protein-1 (AP-1), which redirects MHC-I molecules to early endosomes and then 
lysosomes for degradation3, 7, 8.  One obvious theme between these two mechanisms is the 
binding of the cytoplasmic tail domains of MHC-I and CD4, which leads to the 
recruitment of cellular adaptor proteins.  Further investigation is required to determine 
whether Nef downmodulates NKG2D ligands by a similar mechanism. 
An initial characterization of Nef-mediated NKG2D ligand downmodulation was 
done in collaboration with a former graduate student, Elizabeth Wonderlich.  In these 
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studies, the downmodulation phenotype of CD4, MHC-I and NKG2D ligands was 
compared in primary T cells and CEM-SS CD4+ T lymphoblastoid cells.  Mock-infected, 
PHA-stimulated primary T cells express low levels of NKG2D ligands and high MHC-I 
and CD4 (Figure A2.1a, shaded histogram).  However, mock-infected CEM-SS cells 
constitutively express NKG2D ligands, MHC-I and CD4.  The differences in baseline 
NKG2D ligand expression between these cell types allowed us to determine whether Nef 
removes pre-existing NKG2D ligand surface expression or inhibited the expression of 
new ligands.  As shown in Figure A2.1, NKG2D ligand expression in mock-infected and 
full-length HIV-infected primary T cells is low and then increases in NL-PInef - infected 
cells (part a, top panel).  This may suggest that Nef limits the presentation of NKG2D 
ligands at the surface of the cell.  Alternatively, MHC-I and CD4 expression is 
downmodulated from the surface in full-length HIV-infected primary T cells compared to 
Nef-deficient HIV-infected (Figure A2.1a, compare dashed and bold histogram lines), 
indicating that Nef downmodulates MHC-I and CD4 surface expression on primary T 
cells.   
To compare the downmodulation of NKG2D ligands, MHC-I and CD4 in CEM-
SS cells, a previously described Adenoviral system of expressing Nef in CEM-SS cells 
was used9, 10.  In this system, CEM-SS cells stably expressing HLA-A2 (CEM-A2) were 
transduced with increasing MOI of a Nef-expressing or negative control Adenovirus and 
the surface expression of NKG2D ligands, HLA-A2 and CD4 were determined by flow 
cytometry (Figure A2.1b).  As was seen in primary T cells, Nef reduced the surface 
expression of HLA-A2 and CD4 in CEM-A2 cells (Figure A2.1b). However, there was 
no downmodulation of NKG2D ligands from the surface of CEM-A2 cells, even at the 
highest MOI tested, which expressed a similar amount of Nef as primary T cells (Figure 
A2.1b and c).  These data further suggested that Nef does not downmodulate pre-existing 
NKG2D ligand from the surface; Nef limits the expression of NKG2D ligands.   
Further analysis is required to determine the mechanism of Nef-mediated NKG2D 
ligand inhibition.  The mechanism of Nef-mediated CD4 and MHC-I downmodulation 
involves binding to the cytoplasmic tail domains of these molecules.  However, the 
NKG2D ligands that are upregulated by HIV, the ULBPs, are GPI-anchored proteins and 
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lack a cytoplasmic tail domain.  Therefore, it would be surprising if Nef affected their 
expression by a similar mechanism as CD4 and MHC-I.  Additional study of the NKG2D 
ligand inhibition may reveal a novel Nef mechanism of affecting protein surface 
expression. 
Methods 
HIV-1 and Adenovirus transduction 
PHA-stimulated primary T cells were transduced with NL-PI or NL-PInef - 
molecular clones as described in Chapter 2.  Nef-expressing or control Adenovirus 
transduction of CEM-SS cells was performed as previously described9, 10.  Cells were 
analyzed by flow cytometry as described in Chapter 2.  
Western Blot Analysis 
72 hours after Adenovirus transduction or 48 hours after HIV infection, cells were 
washed in PBS (Invitrogen) and lysed in 0.1% SDS 0.3% CHAPS PBS with 1 mM 
PMSF.  Lysates were normalized for both protein concentration and viral transduction 
and were analyzed by Western blot using an antibody against Nef (AG11 at 1 mg/ml, 
1:500, a gift from J. Hoxie, University of Pennsylvania, Philadelphia, PA11) followed by 
an HRP-conjugated secondary antibody.  The membranes were developed with ECL Plus 
Western Blotting Detection kit (Amersham). 
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Figure A2.1: Comparative downmodulation of NKG2D ligands, HLA-A2 and CD4 
by Nef. 
(a) PHA-stimulated primary T cells infected with NL-PI (dashed line) or NL-PInef - 
(black line) viruses were analyzed for NKG2D ligand, MHC-I and CD4 surface 
expression by flow cytometry.  Mock-infected cells (shaded histogram) were included as 
control.  (b) CEM-SS cells stably expressing HLA-A2 transduced with increasing MOI of 
Nef-expressing (dashed line) or control (black line) Adenovirus were analyzed for 
NKG2D ligand, HLA-A2 and CD4 surface expression by flow cytometry.  Isotype 
antibody staining (shaded histogram) was included as control.  (c) Western blot analysis 




















Figure A2.1: Comparative downmodulation of NKG2D ligands, HLA-A2 and CD4 by Nef.  
